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Particulates incorporating DNA provide for protection and sustained release of DNA, and
thus are promising candidates for DNA delivery systems. Among the routes of
administration for gene delivery, the oral route is perhaps the most appealing as it is
associated with patient comfort and compliance and allows for targeting to intestinal
targets for therapeutic and vaccination applications. With the goal of realizing the
potential of an oral DNA delivery system, zein, a hydrophobic protein from corn that is
biocompatible and degraded enzymatically, was investigated. This thesis describes the
formulation of zein nanospheres encapsulating DNA by a coacervation technique and
their characterization. Zein/DNA nanospheres ranged from 57.8 ± 3.9 nm to 396.8 ±
16.1 nm and from -21.8 ± 4.2 mV to -46.6 ± 1.6 mV for hydrodynamic diameter and zeta
potential measured in water, respectively. Spheres formed at all ratios aggregated to
some degree in PBS, with 20:1 and 40:1 zein:DNA spheres flocculating; aggregation was
found to be dependent on salt concentration. DNA encapsulation efficiency was as high
as 65.3 ± 1.9% with a maximum loading of 6.1 ± 0.2 mg DNA/g zein. DNA that was
encapsulated and released retained its integrity. Release studies indicated that zein was
degraded primary enzymatically with slow release of DNA in PBS, and faster release in
pepsin containing media, and nearly instantaneous release in simulated intestinal fluid.
Spheres demonstrated similar biocompatibility at high and low concentrations, and

showed cellular association and evidence of internalization. Possible improvements to
this delivery system include increasing loading, improving stability against aggregation,
increasing resistance to enzymatic degradation, and improving internalization, nuclear
localization, and transfection. The spheres formed and characterized as described in this
thesis show great potential for oral gene delivery, and with judicious modification should
be rendered even more likely to be applied clinically in oral gene delivery as well as
tissue engineering and intramuscular injection applications.
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Chapter 1
1.1 Introduction
While the application of nonviral gene delivery to gene therapy, tissue engineering, and
DNA vaccination comes with numerous advantages, there are many hurdles that still
must be overcome to achieve such therapies with clinical relevance. Gene therapy
involves the correction of deleterious aberrant genes or supplementing these defects with
genes expressing the correct product. Also, DNA vaccination modulates an immune
response that can result in subsequent immunity when challenged by infection by
transfecting cells with DNA that encodes an antigen, which is then produced by the cell.
Because the oral route is the least invasive route and is associated with high patient
compliance, it is appealing for both nonviral gene therapy and DNA vaccination.
Nonviral gene delivery via the oral route for gene therapy and DNA vaccination has the
potential to revolutionize the treatment and prevention of various ailments, by eliminating
the need for administration by healthcare professionals and enhancing convenience to the
patient. The feasibility of oral delivery has been demonstrated in numerous studies in
animals. Barriers to efficient oral gene delivery, specifically the low pH in the stomach,
degradation by enzymes in the stomach and intestine, and inefficient uptake in the
intestine, have prevented the application of nonviral gene delivery. Therefore, there is a
need to realize the potential of a novel material to overcome these obstacles. Zein, a
protein from corn, is readily available and has physical properties which can be tailored
to specific applications by modifications such as crosslinking, plasticizing, and
copolymerization. It also has biological properties including enzymatic degradation and
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biocompatibility of the protein and degradation products that make it well suited for the
development of nonviral gene delivery systems specifically for the oral delivery of DNA.

1.2 Nonviral gene delivery
Gene delivery, the introduction of exogenous DNA to a cell, has applications in several
areas. This thesis focuses on applications in gene therapy and DNA vaccination. To this
end there are two main modes of gene delivery: viral and nonviral. While viral methods
are effective, eliciting a high rate of transduction and long-term expression, there are
associated safety concerns. The primary problems with viral vectors are their
immunogenicity, lack of specificity and potential for insertional mutagenesis (Thomas,
Ehrhardt, & Kay, 2003). The use of viral vectors for gene therapy in clinical trials has
been tied to a death and the development of a leukaemia-like disorder in several subjects
(Thomas, Ehrhardt, & Kay, 2003). There are also technical problems with viral vectors
including limits to the size of the transgene that they can carry and issues related to their
production (Gao, Kim, & Liu, 2007). Because of these technical and safety issues, the
introduction of plasmid DNA (pDNA), which is nonintegrative and nonreplicating, has
lower immunogenicity, has more flexibility in transgene capacity, and has the potential
for industrial production, is an appealing alternative to viral gene delivery. The use of
nonviral vectors for gene delivery is hindered, however, by relatively low transfection
efficiency as several intra- and extracellular barriers exist that prevent high levels of gene
delivery and expression. Nonetheless, the biocompatibility and potential of scaled-up
production of these delivery vehicles has spurred on research aimed at overcoming these
barriers and improving transfection efficiency (Mintzer & Simanek, 2009).
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There are two main classifications of nonviral gene delivery techniques, namely physical
and chemical methods. In physical methods of nonviral gene delivery, DNA may be
delivered unprotected and uncondensed, termed naked DNA delivery, bypassing the first
hurdle of complexation or encapsulation. However, naked DNA delivery using
electroporation, gene gun or direct injection techniques is of little clinical relevance for
gene therapy due to low levels of transfection (Mintzer & Simanek, 2009). These
techniques may be appropriate for applications were limited transfection is acceptable,
namely, vaccination (Cotten & Wagner, 1993). Under physiological conditions DNA is
negatively charged as are the plasma membranes of the cell and the resultant repulsive
forces as well as the large size of plasmid DNA prevent widespread internalization of
naked DNA (Segura & Shea, 2001). In chemical methods of nonviral gene delivery, the
first step is typically complexation, which involves the condensation and charge
neutralization of DNA by positively charged polymers, lipids, dendrimers, or
polypeptides (Mintzer & Simanek, 2009). DNA can also be encapsulated in nano- or
microparticles (Mintzer & Simanek, 2009) which can protect DNA from degradation,
facilitate in vivo distribution, and release of DNA in a sustained manner (Panyam &
Labhasetwar, 2003). Although various chemical and particulate-based methods exist for
nonviral gene delivery, the barriers that must be overcome are, for the most part,
universal.

The barriers to efficient gene delivery by particles and vectors include internalization,
endosomal escape, nuclear localization, and expression. Packaged DNA must first be
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internalized by endocytosis, fluid phase pinocytosis, or phagocytosis (Agarwal &
Mallapragada, 2008; Pichon, Billiet, & Midoux, 2010). Endocytosis may occur by
clathrin-dependent or –independent (i.e. caveolae mediated) pathways for complexes and
nanospheres (Mintzer & Simanek, 2009), while microspheres are taken up by
phagocytosis (Agarwal & Mallapragada, 2008). DNA delivery vehicles may also be
targeted to specific receptors that mediate internalization (Pichon, Billiet, & Midoux,
2010). Once internalized, the DNA must escape the endosome without being degraded
by low pH or enzymes. This escape is believed to occur by disruption of the endosomal
membrane, or through a proton sponge effect that causes the endosome to rupture
(Mintzer & Simanek, 2009). The DNA must then navigate through the cytosol to the
nucleus. This process is to some degree impeded by the cytoskeleton which may act as a
sieve (Mintzer & Simanek, 2009) with nonspecific binding to cytoskeletal proteins
impairing DNA mobility (Pichon, Billiet, & Midoux, 2010). There is also the possibility
of degradation by enzymes in the cytosol (Mintzer & Simanek, 2009). In non-dividing
cells nuclear internalization through pores in the nuclear membrane is necessary for the
transgene to gain access to the transcription machinery, whereas, in dividing cells vectors
can enter the nucleus when the nuclear membrane breaks down and reforms (De Laporte,
Rea, & Shea, 2006). Complexes and free DNA are too large to pass through nuclear pores
and are therefore likely transported into the nucleus by ATP-dependent pathways similar
to those responsible for the transport of proteins into the nucleus or enter the nucleus
during mitosis (Mintzer & Simanek, 2009). Nuclear localization signals can help mediate
this process (Pichon, Billiet, & Midoux, 2010). At some point during the endosomal
escape/nuclear localization process, the DNA must disassociate from the complex or be
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released from the nano- or microsphere to allow expression. This disassociation is
thought to take place at different points in transport for different types of vectors (Pichon,
Billiet, & Midoux, 2010). In vivo transfection is further complicated by instability of
complexes under physiological conditions and adsorption of serum proteins prior to
cellular internalization (Mintzer & Simanek, 2009). The design of particulates and
complexes able to effect high levels transfection must take into account these barriers and
include tactics to overcome them. Particulates designed in this way have the potential to
result in high levels of transfection over extended periods of time as the DNA is protected
and released. As transfection is transient, particulates ability to extend the duration of
expression makes them appealing for the delivery of DNA.

1.2.1

Particulate DNA delivery

Particulates for DNA delivery, including nanoparticles or microparticles, can consist of
systems where the active compound, DNA, is entrapped within the particles or adsorbed
or conjugated to the surface of the particles (Panyam & Labhasetwar, 2003). Particulates
for gene delivery have been utilized as tools to administer DNA in a controlled,
sustained, and localized/targeted manner (Agarwal & Mallapragada, 2008; Panyam &
Labhasetwar, 2003). Encapsulation of DNA into particles has the potential to improve in
vivo response and transfection by shielding the CpG methylation patterns of plasmid
DNA from the immune system, shielding the plasmid from degradation by pH and
enzymes, and increasing residence time (Agarwal & Mallapragada, 2008). Polymeric
particulates can encapsulate naked DNA or polyplexes, which are composed of DNA
complexed with a cationic polymer (Agarwal & Mallapragada, 2008). Nanoparticles and
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microparticles that are small enough to be internalized by endocytosis or phagocytosis
could potentially serve as intracellular gene depots. Unless the particles themselves are
located in the nucleus, transfection by this released DNA requires nuclear localization.
Microspheres which cannot be internalized by endocytosis could be designed to remain in
the extracellular area of tissues and release their encapsulated DNA; this would also serve
as a controlled and local delivery mechanism (Pannier & Shea, 2004). Release of
entrapped DNA occurs due to a combination of diffusion through and degradation of the
polymer matrix (Agarwal & Mallapragada, 2008). Particulates encapsulating DNA have
the potential to be used in gene therapy and DNA vaccination.

1.2.2 Gene therapy
The definition of gene therapy includes the modification of, removal of, or addition of
genetic material specifically aimed at affecting a phenotypic change in patients with
genetic defects (Drugan, Miller, & Evans, 1987). The state of the art of gene therapy
entails either the introduction of the corrected gene or the direction of cells to produce a
protein or regulatory RNA which would block the harmful effects of the defective gene
(Berns, 2010). These techniques can be used to treat genetic diseases like cystic fibrosis,
hemophilia, and cancer (Bowman, Sarkar, Raut, & Leong, 2008; Montier et al., 2004;
Schatzlein, 2001). While most studies in gene therapy involve the use of viral vectors,
nonviral vectors remain promising tools for gene therapy. Current efforts in the realm of
nonviral gene delivery are aimed at developing selective, safe, and efficient methods of
delivering genes to an individual’s cells for the correct production of gene products
associated with genetic disease (S. Li & Huang, 2000). Gene therapy is a possible
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application of the DNA-encapsulating particulates produced by the methods outlined in
this thesis.

1.2.3 DNA vaccination
DNA vaccination requires the transfection of cells that results in the production of an
antigen. DNA vaccines preserve the native protein structure of the antigen, induce
cytotoxitc T lymphocytes (CTLs), and lack the potential virulence and toxicity associated
with attenuated organisms or recombinant viral or bacterial vectors (O'Hagan, Singh, &
Ulmer, 2004). Because DNA vaccination is typically performed using intramuscular
injection or a gene gun, the cells usually transfected and responsible for antigen
production are myocytes in the muscle and keratinocytes or Langerhans cells in the skin.
The antigen can then be presented to cells of the immune system eliciting an antibody
response. Additionally, CTLs are induced in two ways. The antigen can be processed
and produced by antigen-presenting cells (APCs) or the antigen can be produced by nonAPCs and transferred to APCs. Plasmids used in DNA vaccination also have adjuvant
properties due to their CpG methylation motifs. Despite its advantages and successes in
animal models, DNA vaccination in clinical trials has primarily been limited to naked
DNA delivery methods and has not been found to be efficient in most cases of human
application. However, there have been a couple of promising results offering proof of
concept for this vaccination technique (O'Hagan, Singh, & Ulmer, 2004). The
development of a zein nano- or microsphere capable of transfection would result in a
possible delivery system for DNA vaccination. Important to the utility of particulates in
both gene therapy and DNA vaccination is an appropriate route of administration.

8

1.2.4 Oral route of administration
The oral route of administration is associated with high patient compliance and
convenience. Because nonviral gene delivery is transient and would require repeated
administration for gene therapy applications, ease of administration and patient comfort
are particularly important. The cellular structure of the intestine epithelium and gutassociated lymphoid tissue (GALT) is crucial to the oral absorption profile of a
compound or delivery system. A single layer of epithelial cells makes up the intestinal
epithelial barrier. It is composed of primarily enterocytes with goblet cells, which secrete
mucus, interspersed. GALT consisting of lymphoid follicles are found throughout the GI
tract (gastro-intestinal tract). Organized clusters of these follicles are called Peyer’s
patches which are overlayed with a layer of epithelium that is set apart from other
intestinal epithelium by the presence of M-cells (microfold cells, (Clark, Jepson, & Hirst,
2001).

For the oral route of administration, biodegradable particulate carrier systems have the
potential to improve bioavailability, target certain organs, improve gastric tolerance of
agents that are stomach irritants and serve as a carrier for antigens in oral immunization
compared to unencapsulated drugs (Desai, Labhasetwar, Amidon, & Levy, 1996). The
oral route has the additional advantages of presenting a large surface area of intestinal
epithelium for transfection and allowing treatment of regional disorders by providing
access to the luminal side of the intestine (Bhavsar & Amiji, 2007). Particulates are
considered a viable tool for the protection of DNA from the harsh environment of the
stomach and intestine. However, the limited oral absorption of these particulates has
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hampered their efficiency (H. Chen & Langer, 1998). Mucoadhesion, or association with
the mucous layer of the GI-tract, has been proposed as a means of increasing the
residence time of particulates encapsulating DNA as well as their proximity to the
underlying intestinal epithelium. Chen and Langer point out that the turnover time of the
mucous layer is only slightly longer than the normal intestinal transit time (H. Chen &
Langer, 1998). However, it does appear that bioadhesion to the underlying epithelium is
an effective way of increasing residence time (Mathiowitz et al., 1997). Other means of
improving transfection in the GI-tract include targeting glycoproteins and receptors of the
intestine, using chemical enhancers to promote absorption, and using mucolytic agents to
reduce the mucous layer (Page & Cudmore, 2001). An ideal particulate gene delivery
system would incorporate properties allowing it to protect the payload of DNA in the
stomach and intestine and facilitate a high level of uptake by cells lining the intestine. To
this end, zein was investigated in the studies described in this thesis as a possible oral
delivery system. As described below, zein is a promising candidate material for oral
delivery.

1.2.4.1 Oral gene therapy
Oral gene therapy has the potential to treat patients suffering from diseases directly
associated with the GI-tract (e.g. familial adenomatous polyposis, cystic fibrosis, various
colon cancers, inflammatory bowel disease, and Crohn’s disease) (Page & Cudmore,
2001) as well as systemic diseases (Rothman, Tseng, & Goldfine, 2005). The use of oral
administration to treat diseases affecting the GI-tract is quite appealing as this route
allows direct access to the affected tissue and thus no further transport of the gene or the
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encoded protein is required. The diseased state of these tissues may also allow for
additional targeting due to different receptor expression compared to healthy tissue (Page
& Cudmore, 2001). Local nonviral gene therapy within the GI-tract was demonstrated by
Bhavsar and Amiji with their nanoparticles-in-microsphere oral system. Using a murine
model of acute colitis it was demonstrated that delivery of murine IL-10 expressing
plasmid resulted in a reduction in the levels of proinflammatory cytokines and certain
chemokines. This therapy also resulted in an increase in body weight, good clinical
activity scores, restoration of colon length and weight, and reduction in inflammatory
response (Bhavsar & Amiji, 2008). This study indicates a possible use of zein/DNA
nanospheres for gene therapy for diseases affecting the GI-tract.

Proof-of-principle for the oral delivery of DNA was provided by Rothman et al. Rothman
and coworkers proposed oral gene therapy as a more convenient and easier to
manufacture alternative to protein pharmaceutics for systemic therapy (Rothman, Tseng,
& Goldfine, 2005). They further hypothesized that protein could be manufactured in the
cells of the intestine, could be delivered into the bloodstream, and could act elsewhere in
the body. For this application nonviral gene delivery requires frequent dosing like other
oral medications, but this allows the dose to be altered on a daily basis and allows
treatment to be stopped in the case of adverse side effects. To provide proof of this
principle they administered naked DNA in a number of ways: injected into an isolated
segment of the duodenum, through an indwelling catheter placed in the intestinal lumen,
injected into a patent duodenum, and by oral gavage. Delivery of the luciferase gene to
ligated, and unligated duodenums and via oral gavage showed that expression occurred in
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the intestine and was significantly higher than control for all cases. It should be
mentioned that transfection as a result of plasmid delivered by oral gavage was onefourth to one-fifth of that of plasmid injected directly into the duodenum. Plasmid
encoding human growth hormone (hGH) was used to assess the ability of orally
administered plasmid to elicit the production of protein with subsequent delivery of the
protein into the bloodstream. Twenty-four hours post-administration to the duodenum of
rats, plasmid encoding hGH resulted in hGH levels at five times background levels in the
blood. Five days of such treatment resulted in maintained elevated levels that fell to
background upon the cessation of the treatment. The ability of the administration of
plasmid DNA to affect a physiological change was evaluated using a plasmid encoding
insulin in diabetic mice. Delivery of plasmid to isolated duodenal segments resulted in
blood glucose levels that remained at or close to non-diabetic values for about two days
before rising into the diabetes range. The effect was transient but reproducible with
repeated dosing. These results led Rothman and coworkers to conclude that oral gene
therapy had great potential but required improvement in DNA packaging and protection
from degradation and improvements in the efficiency and reliability of transfection
(Rothman, Tseng, & Goldfine, 2005).

Previously polyanhydride copolymers of fumaric and sebacic acid were used to form
microspheres encapsulating pCMV/β-gal that were delivered orally. Histochemical
staining of Peyer’s patches showed that most transfected cells were located in the
muscularis mucosae and adventitia below the Peyer’s patches for encapsulated DNA,
whereas there were was no false-positive staining in the Peyer’s patches of rats that
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received naked DNA or no DNA (Mathiowitz et al., 1997). Oral administration of the
mEpo gene in chitosan nanoparticles resulted in a significant increase in hematocrit
measured in the blood compared to control upon first and second feedings (J. Chen et al.,
2004). Similarly Bowman et al. orally administered Factor VIII DNA in chitosan
nanoparticles and achieved a physiological effect. Hemophilia A mice that were fed
chitosan/DNA nanoparticles underwent a phenotypic correction in 13 out of 20 cases,
compared to 1 out of 13 cases for naked plasmid (Bowman, Sarkar, Raut, & Leong,
2008). In another study, parathyroid hormone (PTH)(1-34) gene was orally
admininstered to parathyroidectomized rats in polyethylene oxide-polypropylene oxidepolyethylene oxide polymeric micelles. This treatment resulted in 100% survival with
normal activity and appetite and significantly higher serum calcium and serum PTH(134) levels as compared to controls (Chou, Huang, Chang, Liaw, & Hung, 2009). These
studies demonstrate the feasibility and promise of oral gene therapy to treat a variety of
systemic diseases. The possible treatment of systemic diseases makes the development
of a particulate zein/DNA system capable of oral absorption and transfection extremely
useful to individuals with a wide variety of diseases.

1.2.4.2 Oral DNA vaccination
The oral route of delivery is particularly appealing for vaccination because it is less
invasive than current treatment methods and because it facilitates access to GALT.
Immunization at GALT could provide an effective barrier to infections gaining entry
through mucosal surfaces (Jones, Clegg, & Farrar, 1998). The high transcytotic capacity
of M-cells also aids in the absorption of other particulates making them a common target
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for delivery systems specifically for oral vaccination due to the proximity of M-cells to
cells belonging to the immune system (Clark, Jepson, & Hirst, 2001). As microspheres
are too large to be taken up by endocytosis, size exclusion can lead to their preferential
uptake by phagocytic cells like M-cells. Hence, primarily microspheres have been
studied as carriers for DNA vaccination (Agarwal & Mallapragada, 2008).

Oral DNA vaccination was first demonstrated in 1997 by Jones and coworkers with
orally administered DNA encapsulated in poly(lactic-co-glycolic acid) (PLGA)
microspheres eliciting both a systemic and a mucosal antibody response (Jones, Corris,
McDonald, Clegg, & Farrar, 1997). These results have led to many studies using
synthetic and natural polymers to encapsulate and deliver DNA via the oral route for
DNA vaccination. Jones et al. compared oral DNA vaccination to intraperitoneal
injection and found that oral administration resulted in lower but significant IgG titres,
similar IgM titres and higher IgA titres (Jones, Clegg, & Farrar, 1998). The induction of
immunity to measles using DNA encoding the measles virus nucleocapsid protein was
evaluated by Fooks and coworkers (Fooks, Sharpe, Shallcross, Clegg, & Cranage, 2000).
They found that the administration of plasmid DNA encapsulated in PLGA resulted in an
increase in specific IgG antibody titers in three of ten mice, whereas viral oral
vaccination had a 100% induction of IgG titer increase (Fooks, Sharpe, Shallcross, Clegg,
& Cranage, 2000). These results indicated that there was much room for improvement in
the efficacy of nonviral oral DNA vaccine vehicles. However, several other studies have
shown more promising results. PLGA microparticles containing plasmid encoding
hepatitis B virus HBsAg induced a long-lasting and stable antigen-specific antibody, in
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both serum and intestinal IgA, and CTL responses in BALB/c mice (He et al., 2005).
Mice immunized with microparticles encapsulating HIV protein encoding plasmid by
oral vaccination showed a multifaceted envelope-specific immune response and higher
resistance to mucosal viral transmission than mice injected intramuscularly with plasmid
encoding the same protein (Kaneko et al., 2000). DNA vaccines encoding allergens like
the dermatophgoides pteronyssinus (Der p) allergen from dust mites and a dominant
peanut allergen have been used to prevent sensitization of IgE reactions in mice. DNA
vaccination may be used to modify the ongoing Th2-type immune response in allergic
diseases by inducing a dominant Th1 response (G. Li, Liu, Liao, & Zhong, 2009). Mice
that received chitosan nanoparticles encapsulating a gene for a dominant peanut allergen
were significantly less likely to suffer from allergen-induced anaphylaxis and had
reduced levels of IgE, plasma histamine, and vascular leakage (Roy, Mao, Huang, &
Leong, 1999). Li et al. found that oral delivery of chitosan/pDer p 2 nanoparticles
resulted in the expression of Der p 2 in both the stomach and small intestine, prevention
of sensitization of the Th2 cell-regulated specific IgE response, and the induction of Th1type immune response (G. Li, Liu, Liao, & Zhong, 2009). These studies provide
evidence of the promise of oral DNA vaccination in combating infection and in treating
disorders of the immune system, making DNA vaccination a prospective application of
DNA-encapsulating zein nano- and microspheres.

1.2.5

Materials for oral DNA delivery

Synthetic materials for DNA delivery offer a higher degree of control and uniformity of
properties and generally provide a more sustained release than natural materials.
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However, they also may require the use of harsh solvents and may have detrimental
degradation products. The most commonly used synthetic polymer for oral gene therapy
and vaccination applications is PLGA. It is approved by the FDA and has been used for
internal sutures, implants, and drug and protein delivery with a documented history of
safe use (Abbas, Donovan, & Salem, 2008; Jones, Clegg, & Farrar, 1998). It is a
biodegradeable polymer that degrades by non-enzymatic hydrolysis to two normal
metabolites, lactic and glycolic acids (Jones, Clegg, & Farrar, 1998). However the acidic
nature of these degradation products can lead to the degradation of encapsulated DNA.
This degradation can be avoided by forming PLGA nanospheres. Nanospheres have the
advantage of a large surface area to volume ratio which promotes diffusion of lactic and
glycolic acids away from the particle, thereby preventing DNA degradation (Agarwal &
Mallapragada, 2008). Encapsulation of DNA in PLGA particles by these methods is
complicated by the hydrophobic and hydrophilic natures of PLGA and DNA,
respectively, and the large size of DNA (Agarwal & Mallapragada, 2008). Release
profiles of encapsulated DNA can be affected by the composition and molecular weight
of the PLGA polymers (Agarwal & Mallapragada, 2008; Jang & Shea, 2006). Various
modifications can be made to improve the formulation and DNA delivery performance of
PLGA particles including the use of surfactants and excipients, and covalent
modifications like PEGylation and the addition of diethylaminopropylamine substituents
(Abbas, Donovan, & Salem, 2008). Other synthetic polymers that have been used very
limitedly to form DNA containing particles for oral delivery include polyanydride
copolymers of fumaric and sebacic acid (Mathiowitz et al., 1997) and poly (εcaprolactone)(PCL) (Bhavsar & Amiji, 2007).
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Natural polymers have also been applied to drug/gene delivery. Natural materials have
an advantage over synthetic biomaterials in that these natural biomaterials provide innate
degradability, biocompatibility, and bioactivity (Dang & Leong, 2006). The most
commonly used natural polymer for the formation of DNA-containing particles is
chitosan. Chitosan is a polysaccharide obtained by between 66% and 95% deacetylation
of chitin (abundantly available in marine crustaceans) and is biocompatible and
biodegradable (Agnihotri, Mallikarjuna, & Aminabhavi, 2004). Chitosan contains many
primary amine groups that endow it with properties that make it pharmaceutically useful
(i.e., give it a positive charge and mucoadhesive properties) (Agnihotri, Mallikarjuna, &
Aminabhavi, 2004). Chitosan has been intensively studied for oral delivery applications
due to its ability to increase paracellular permeability in the intestinal epithelium by
interfering with tight junctions (Bowman & Leong, 2006). The properties and
transfection efficiency are affected by the ratio of nitrogens from chitosan to
phosphoruses from DNA (N/P ratio), chitosan molecular weight, degree of acetylation,
and modification of chitosan including attachment of targeting ligands and addition of
endosomolytic compounds like polyethyleneimine (PEI) (Bowman & Leong, 2006).
Other natural polymers that have been used for the oral delivery of DNA include collagen
(Jun Wang et al., 2004), gelatin (Bhavsar & Amiji, 2007), and alginate (Mittal et al.,
2001), however their application to oral DNA delivery is not common.

1.2.6 Investigating new materials
To date many advances have been made toward the development of therapies that utilize
nonviral gene delivery, specifically in the realm of micro- or nanoparticles that
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encapsulate and deliver plasmid DNA. However, no delivery system can meet the
demands for therapeutic action in humans. There are a number of prerequisites for
success in gene delivery applications including high DNA encapsulation efficiency and
loading within the particles, stability of DNA in the particle, nontoxicity of the particle
and its degradation products and the ability to facilitate transfection. Oral delivery
further requires protection of the payload from the acidic environment and enzymes of
the stomach, protection of the DNA from enzymes in the intestine, facilitation of
transport of DNA across the mucous layer, and mediation of transfection of intestinal
cells or passage through the intestinal epithelium into circulation and subsequent
transfection. The investigation of new materials, and modifications thereof, which have
the ability to meet these requirements promises to fuel more breakthroughs and bring
nonviral gene delivery via oral administration closer to clinical application. Due to its
demonstrated ability to deliver drugs orally, zein has been investigated in this thesis for
the oral delivery of DNA.

1.3 Zein
Zein is the prolamin, or storage protein, of corn. Protein comprises 6-12% (db) of corn
depending on the variety, and approximately 75% of that protein is found in the
endosperm (Shukla & Cheryan, 2001). Zein, which accounts for approximately 45-60%
of the total corn protein, is found exclusively in the endosperm (Anderson & Lamsal,
2011; Shukla & Cheryan, 2001). Protein bodies, membrane-bound subcellular
compartments, typically around 1 µm in diameter, are formed within the endoplasmic
reticulum as deposits of zein and are located in the cytoplasm between starch granules
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(Duvick, 1961; Larkins & Hurkman, 1978). Zein serves as nitrogen sink, facilitating the
transport of photosynthates into the kernel as the seed develops, and later is used by the
germinating plant as a source of nitrogen (Mohammad & Esen, 1990; Tsai, Huber, &
Warren, 1980). The properties of zein, as determined by its structure, vary widely
depending upon protein fraction, processing, environmental conditions, chemical
modifications and degree of degradation. The physicochemical properties of zein can be
tailored to a number of applications as evidenced by its various past uses. Today zein is
used in pharmaceutical tableting and coating, and is considered most promising for
applications in edible and biodegradable packaging and coatings as well as biomedical
applications (Lawton, 2002). Zein has shown great potential in the field of drug delivery
as it has the potential for a wide range of potential modifications, excellent
biocompatibility and biodegradability (undergoing enzymatic degradation) (S. Gong,
Wang, Sun, Xue, & Wang, 2006; Mathiowitz, Bernstein, Morrel, & Schwaller, 1993;
Sun, Dong, Lin, Yang, & Wang, 2005). In this thesis zein was used to for nano- and
microspheres encapsulating DNA for the first time. A background on zein is presented
below.

1.3.1 History
Zein was discovered and named by John Gorham in 1821, but it was not classified as a
prolamin until Osborne did so in 1924 (Anderson & Lamsal, 2011; Lawton, 2002;
Osborne, 1924).The first patent for extracting zein was issued to Osborne in
1891(Lawton, 2002; Osborne, 1891b), however, the first facility for the production of
zein did not open until the late 1930’s (Anderson & Lamsal, 2011; Lawton, 2002; Shukla

19

& Cheryan, 2001). At the peak of zein production, there was a total output of about 15
million pounds per year (Anonymous, 1978). From the late 1800’s to today, numerous
applications for zein have been identified including coatings, fibers, inks, adhesives and
plastics (Bers, 1945; Coleman, 1939, 1941; Osborne, 1891a; Swallen, 1939). Zein has
been supplanted in many of its former applications due to the development of synthetics
with superior properties and lower costs. In many applications zein has been plagued by
its prohibitive cost and its poor resistance to water (Lawton, 2002). Zein is currently
used to coat materials that remain dry, namely, nuts and pharmaceuticals. Unless its
hygroscopic nature can be overcome, zein will continue to be limited to applications
where its change in moisture content with relative humidity will not affect its
performance (Lawton, 2002). Today zein is manufactured commercially by four
companies: Freeman Industries (Tuckahoe, NY), Showa Sangyo (Tokyo, Japan), POET
Inc. (Sioux Falls, SD) and Prairie Gold Inc. (Bloomington, IL), with Freeman Industries
and Showa Sangyo responsible for the bulk of zein production (Anderson & Lamsal,
2011). The current, relatively high price of zein, $10-40/kg (Anderson & Lamsal, 2011),
compared to the estimated cost of extraction, $2-3/kg (Dickey, McAloon, Craig, & Parris,
1999), has been attributed to the lack of demand (Lawton, 2002). Shukla asserts
however, that the high price is due to the large amount of organic solvents used and the
energy-intensive processes, such as distillation and evaporation, needed in zein
production (Shukla & Cheryan, 2001).
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1.3.2 Fractions
Zein nomenclature is rather convoluted. Shukla and Cheryan counted at least five
systems of naming the various zein fractions (Shukla & Cheryan, 2001). In this thesis
Esen’s system will be used. In Esen’s system, which was proposed in 1987, α (75-85%
of total zein, 21-25 kDa and 10 kDa), β (10-15% of total zein , 17-18 kDa), and γ (5-10%
of total zein, 27 kDa) zein were separated based on their varying solubility in aqueous
isopropyl alcohol and aqueous isopropyl alcohol/sodium acetate solutions (Esen, 1987).
The system was later revised to include δ zein as the 10 kDa fraction (Esen, 1990). Zein
consists of several fractions that vary in molecular size, charge and solubility. Although
some zein fractions are proteins soluble in aqueous ethanol and a reducing agent rather
than true prolamins, they are found in the protein bodies and are also considered to be
zein (Wilson, 1991). Commercial zein primarily contains only one of these fractions,
namely α zein, sometimes with traces of δ zein (Wilson, 1988).

Lawton attributes the

lack of other fractions in commercial zein to a combination of two factors. First, the
starting material for commercially extracting zein has been treated with sulfur dioxide,
reducing the disulfide bonds in β, γ, and δ zein which increases their water solubility.
Second, the solvent, 86% isopropyl alcohol, used to extract commercial zein is not a good
solvent for these fractions (Lawton, 2002). The lack of these minor fractions is beneficial
to producers as β, γ, and δ zein are thought to cause gelling (Lawton, 2002). Commercial
zein was used for the formation of zein/DNA nanospheres in this thesis.
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1.3.3

Structure

Although many of zein’s properties as they relate to solubility and phase separation can
be explained by what is known about the protein’s primary and secondary structures, the
exact tertiary structure of zein, specifically for α zein, has not been definitively
determined. The amino acid sequence of zein consists of more than 50% nonpolar amino
acids, including high percentages of leucine, proline, and alanine, causing zein to be
insoluble in water. Zein also has a high glutamine content which results in zein’s
insolubility in absolute alcohol (Padua & Wang, 2009; Pomes, 1971). The 19kDa and
22kDa α zein peptides consist of an eight residue long C-terminal end and a 35-37
residue long N-terminal end separated by either nine or ten repetitive sequences that
range in length from 14 to 25 residues averaging 19-20 amino acids (Padua & Wang,
2009). This and other data have given rise to several possible models for the tertiary
structure, but have not yet pointed to a definitive structure (Agros, Pedersen, Marks, &
Larkins, 1982; Bugs et al., 2004; Garratt, Oliva, Caracelli, Leite, & Arruda, 1993;
Matsuda et al., 1989; Padua & Wang, 2009).

1.3.4 Solubility
Zein is soluble in a number of primary, binary and ternary solvent systems, primarily
determined by the balance between the polar/nonpolar groups in those systems. Because
of zein’s large proportion of hydrophobic residues it is not soluble in water at standard
pH. It is however, soluble in water above pH 11 due to the ionization of the tyrosine
phenolic groups and of the few carboxyl groups (Pomes, 1971). Evans and Manley found
that zein was soluble in a number of primary solvents which were all hydroxyl
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compounds, amines, amides or acids with the exception of pyridine (Evans & Manley,
1941). Zein is soluble in organic solvents with hydroxyl, carboxyl, amino, and other polar
groups in proper ratio to nonpolar groups because of its large number of hydrocarbon side
chains (Pomes, 1971). Binary solvents studied by Manley and Evans included systems of
water in combination with a ketone, lower aliphatic alcohol, dioxane, or dioxolane or
lower aliphatic alcohols in combination with a number of compounds including
aldehydes, ketones, nitroparaffins, partially chlorinated hydrocarbons, cyclic ethers,
aromatic hydrocarbons and glycols (Manley & Evans, 1943). Ternary solvents include
systems containing water, a lower aliphatic alcohol and any one of a number of other
compounds or systems containing water and two other compounds including glycols and
butanediols (Evans & Manley, 1944; Shukla & Cheryan, 2001). Depending on the
concentration of aqueous ethanol, the solubility of zein ranges from 2 to 60% (w/w) at
constant temperature (Shukla & Cheryan, 2001). At temperatures below the boiling point
of ethanol, zein is soluble in between 50% and 90% ethanol, with coacervation and
precipitation taking place both above and below this range (Shukla & Cheryan, 2001), the
former of which will be utilized later in this thesis.

1.3.5 Crosslinking
Crosslinking is a modification of zein often investigated to improve its physical
properties. Crosslinking typically affects the tensile strength, elongation and Young’s
modulus of zein fibers and films as well as their solubility in solvent systems that
normally dissolve zein and degree of swelling when soaked in an aqueous solution (Jiang,
Reddy, & Yang, 2010; Kim, Sessa, & Lawton, 2004; Parris & Coffin, 1997; Reddy &
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Yang, 2009; Xu, Karst, Yang, & Yang, 2008; Yao, Li, & Song, 2007). Zein can be
crosslinked by many compounds including glyoxal, hexamethylene diisoyanate,
polymeric dialdehyde starch, 1-[3-dimethylaminopropyl]-3-ethyl-carbodiimide
hydrochloride, formaldehyde, N-hydroxysuccinimide, glutaraldehyde, epichlorohydrin,
citric acid and butanetetracarboxylic acid (Kim, Sessa, & Lawton, 2004; Parris & Coffin,
1997; Yang, Wang, & Li, 1996; Yao, Li, & Song, 2007). Zein can also be crosslinked
enzymatically using the enzymes transglutaminase or protein disulfide isomerase
(Mathiowitz, Bernstein, Morrel, & Schwaller, 1993). Zein nano- and microspheres have
the potential to be crosslinked using the same compounds that are used in films and fibers
(Mathiowitz, Bernstein, Morrel, & Schwaller, 1993). In forming zein microspheres,
glutaraldehyde and trimethylsilyl chloride have been used to modify zein with certain
drugs and likely resulted in additional crosslinking of the zein (Matsuda et al., 1989;
Suzuki et al., 1989). Although nano- and microsphere crosslinking has not been well
investigated, it is conceivable that this type of modification would be useful in altering
properties such as the degradation rate of zein particles. Crosslinking may be required
for the improvement of the stability and release profiles of DNA-loaded zein particles
produced in this thesis.

1.3.6 Other chemical modifications
Zein has also been modified by derivitization of surfaces, forming copolymers, and
deaminization or phosphorylation of its amino acids (Biswas, Selling, Woods, & Evans;
Mathiowitz, Bernstein, Morrel, & Schwaller, 1993; Q. Wu, Yoshino, Sakabe, Zhang, &
Isobe, 2003). Esterification of zein with fatty alcohols or acylation with fatty anhidrides,
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which can alter the acid or base sensitivity of the protein, are other options for chemical
modification of zein. Acylation with fatty anhydrides was demonstrated by adding the
fatty anhydrides to zein containing solution under reactive conditions. The modified zein
was later used to form microspheres encapsulating insulin with different fatty acid
modifications resulting in different release profiles (Mathiowitz, Bernstein, Morrel, &
Schwaller, 1993). By deaminating or phosphorylating the amino acids of zein, the
characteristics, e.g. hydrophobicity, of the protein can be altered (Casella & Whitaker,
1990; Mathiowitz, Bernstein, Morrel, & Schwaller, 1993). Deamination and
phosphorylation of whole zein and zein hydrolysate increased the peptides’ solubility in
water in certain pH ranges. These modifications also affected the emulsifying activities
and stabilities of some of the peptides (Casella & Whitaker, 1990). Mathiowitz et al.
demonstrated that zein could be deamidated and further modified with fatty acids,
hexanoic anhydride, octanoic anhydride, decanoic anhydride, or lauric anhydride. Zein
modified thusly and zein that was deaminated but not modified with a fatty anhydrides
were then used to form microspheres encapsulating insulin, with the various
modifications, again, resulting in differing release profiles (Mathiowitz, Bernstein,
Morrel, & Schwaller, 1993). These studies give examples of the ways in which zein can
be modified and offer evidence of the usefulness of modified zein. Zein microspheres
may require one or more of these modifications to be efficient as gene delivering
vehicles.
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1.3.7 Degradation
Zein is degraded by many enzymes including pepsin, trypsin, thermolysin, collagenase,
milezyme, alcalase, pronase, papain and chymotrypsin (Hurtado-Lopez & Murdan,
2006b; Kong & Xiong, 2006; Mannheim & Cheryan, 1993; Mathiowitz, Bernstein,
Morrel, & Schwaller, 1993; Miyoshi et al., 1991; Sun, Dong, Lin, Yang, & Wang, 2005).
Hurtado-Lopez and Murdan found that while zein was extremely resistant to degradation
in the absence of enzymes, i.e. in chloride buffer (pH 2), acetate buffer (pH 5) and PBS
(pH 7.4), zein was degraded much more quickly by pepsin and pancreatin enzymes found
in gastric and intestinal fluids, respectively, than it was by solutions free of enzymes
(Hurtado-Lopez & Murdan, 2006b). Zein was also hydrolyzed by collagenase, trypsin, or
pepsin and its degradation products were found to have a significant positive effect on
cell proliferation for HL-7702 liver cells and HUVECs with an optimal concentration of
about 0.3 mg/mL (Sun, Dong, Lin, Yang, & Wang, 2005; H.-J. Wang, Lin, Liu, Sheng, &
Wang, 2005). The results of these studies suggest that zein nano- and microspheres
encapsulating DNA will be degraded by enzymes and that their degradation products will
not adversely affect cells.

1.3.8

Biocompatibility

Zein, a natural polymer, has been shown to be very biocompatible. Cell proliferation on
films and electrospun mats composed of zein has been compared to that of cells on a
number of other surfaces composed of compounds commonly used in tissue engineering
and biomaterials. Notably, zein surfaces have consistently outperformed poly(lactic acid)
(PLA) and Corning plates in regard to supporting cell proliferation (Dong, Sun, & Wang,
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2004; Jiang, Reddy, & Yang, 2010; Sun, Dong, Lin, Yang, & Wang, 2005). Cellbiomaterial interactions for zein substrates can be improved with appropriate
modifications. As previously mentioned, crosslinked electrospun zein fiber mats
supported superior cell attachment, spreading and proliferation than uncrosslinked fibers
(Jiang, Reddy, & Yang, 2010). The ability of mesenchymal stem cells (MSCs) to adhere,
grow and proliferate on zein scaffolds was demonstrated with significantly higher
proliferation on zein scaffolds containing stearic acid as a plasticizer compared to
unmodified zein and zein with other plasticizers (H.-J. Wang et al., 2007). Also, the
differentiation of MSCs to osteoblasts on porous zein scaffolds was improved by coating
the scaffold in hydroxyapatite (Qu et al., 2008). Because of zein’s excellent
biocompatibility which can be further improved upon, it is a promising biomaterial for
gene delivery applications. This property as well as the mode of degradation of zein and
its potential for modification make zein nanospheres tools for gene delivery with the
ability to be fine-tuned and tailored to specific applications.

1.3.9

Micro- and nanoparticles

Zein nano- and microspheres have been investigated by several groups for nutraceutical
and drug delivery, usually administered orally. There are several methods for forming
zein micro- and nanospheres, the most common of which is coacervation, or phase
separation. Coacervation is defined as the separation of colloidal systems into two liquid
phases (Gander, Blanco-Prieto, Thomasin, Wandrey, & Hunkeler, 2006). This separation
involves the development of one phase rich in polymer (the coacervate) and another
lacking polymer brought about by the partial desolvation of a previously dissolved
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polymer (Arshady, 1990; Gander, Blanco-Prieto, Thomasin, Wandrey, & Hunkeler,
2006; Madan, 1978). This change in solubility may result from a change in temperature,
pH or electrolyte concentration or from polymer-polymer interactions (Gander, BlancoPrieto, Thomasin, Wandrey, & Hunkeler, 2006; Madan, 1978). As opposed to
precipitation, this process results in a colloidally stable system, although flocculation may
occur making it difficult to distinguish from precipitation (Gander, Blanco-Prieto,
Thomasin, Wandrey, & Hunkeler, 2006; Madan, 1978). In the case of zein, the process
typically begins with zein dissolved in a solvent, e.g. aqueous ethanol, and proceeds with
the addition of a nonsolvent, namely an aqueous solution. The resultant decrease in
ethanol concentration causes the necessary partial desolvation of zein.

When using the traditional coacervation technique, size, encapsulation efficiency,
loading, and release profiles of encapsulated drugs have been shown to be dependent on
several parameters of zein microsphere formation and characteristics of compounds
incorporated. Increasing the zein to encapsulated drug ratio typically results in increased
encapsulation efficiency but decreased loading (Fu, Wang, Zhou, & Wang, 2009b; H.-J.
Wang, Lin, Liu, Sheng, & Wang, 2005). Zein microspheres formed by coacervation
generally release their payload relatively quickly for approximately the first 24 hours
(possibly due to surface-associated drug) followed by a slower sustained release for the
rest of the study, with the released compound maintaining its activity.

There are several examples of the utility of zein nano- and microspheres formed by the
common coacervation technique. These examples include spheres and films comprised
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of spheres. Several studies have shown the potential of these spheres and films to
provide sustained and effective release of the encapsulated compound. Fu et al. formed
zein microspheres and microsphere films encapsulating the antibiotic, ciprofloxacin, for
possible application in films on implanted devices. The loading and encapsulation
efficiencies were relatively low, (size, encapsulation efficiency and loading data for zein
microspheres loaded with nutraceuticals, essential oils, and drugs can be found in
Appendix A.) probably due to the solubility of the drug (relatively hydrophilic). In vitro
release from microsphere films in trypsin-containing solution was observed for up to 28
days and was correlated to the degradation of the films. Bacterial adhesion was
significantly reduced by the release of the antibiotic (Fu, Wang, Zhou, & Wang, 2009a).
Sustained release was also demonstrated for zein microsphere films encapsulating
heparin over 20 days. The released heparin significantly increased the time of clotting
for at least ten days (H.-J. Wang, Lin, Liu, Sheng, & Wang, 2005). In forming zein
microspheres encapsulating polysaccharide-K (PS-K) by first conjugating PS-K to zein,
Matsuda and coworkers found that using appropriate amounts of catalyst, using
glutaraldehyde as the crosslinker, and rapid addition of aqueous solution containing
polyvinylpyrrolidone (PVP) as a stabilizer were crucial for forming mono-disperse
microspheres less than one micrometer in diameter. They also found that release was
dependent on the zein to PS-K ratio as well as the nature of the release media, i.e. pH and
concentration of enzyme (Matsuda et al., 1989). The release profile of zein microspheres
can be further controlled by tabletting. Tabletting zein microspheres encapsulating the
hydrophobic drug, ivermectin, significantly slowed release and resulted in zero order
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release over eleven days and degradation over fourteen days in pepsin containing buffer
(Liu, Sun, Wang, Zhang, & Wang, 2005).

One of the drawbacks of the simple coacervation technique is that the loading of
hydrophilic drugs is often low. However this hurdle to efficient encapsulation has
previously been overcome. Spheres composed of conjugates of zein with antitumor
drugs mitomycin , daunomycin hydrochloride, and peplomycin sulfate were formed using
three methods. Encapsulation of the most hydrophobic drug was relatively
straightforward, while the efficient encapsulation of the moderately and highly
hydrophilic drugs required protocol modifications but resulted in loadings as high as
31.3% and 19.0%, respectively (Suzuki et al., 1989).

Zein has been shown to have great potential for the oral delivery of compounds, as it is
capable of protecting its payload through the stomach. The possibility of oral delivery of
compounds to the intestine was explored by Parris and coworkers who found that less
than half of the zein in the nanospheres that they formed was degraded after four hours in
pepsin-containing solution. This slow degradation would allow the majority of the
spheres to pass through the stomach undegraded and to deliver their payload to the
intestine. Incubation of zein with swine manure solids indicated that digestion would
occur rapidly, possibly within minutes, in the intestine (Parris, Cooke, & Hicks, 2005).
Release of encapsulated essential oils in phosphate buffered saline (PBS) resulted in an
initially rapid release, up to approximately 40-60% over the first ten hours, followed by a
slower phase of release that reached a peak at 60-80% after which no more release was
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detected (Parris, Cooke, & Hicks, 2005). Based on their ability to release encapsulated
drugs in a sustained manner, to maintain drug activity, to be tabletted to alter release, to
encapsulate hydrophilic drugs with the proper modifications, and to deliver their payload
to the intestine, spheres formed using the traditional coacervation technique (the method
used in this thesis) are of particular interest.

Another embodiment of coacervation involves the addition of zein solution to an aqueous
non-solvent. In 1991 Stark and Gross received a patent for their invention entailing
microsphere formation by the addition of hydrophobic protein solution to an aqueous
solution with agitation. They found that microspheres size could be altered by varying
parameters including the concentration of the protein solution, rate of agitation, and
temperature (Stark & Gross, 1991). Zhong and Jin proposed three competing
mechanisms for sphere formation by this method. First is the breakup of the zein solution
into droplets by the shear force, leading to the second mechanism, the solidification of
zein during solvent removal to the aqueous phase. And third, the coalescence of droplets
that have not yet solidified (Zhong & Jin, 2009b). Using this method, zein was dissolved
in various concentrations of ethanol and this solution was sheared into water with a
homogenizer. Diameter was affected by zein concentration, ethanol concentration, shear
rate and homogenizer speed. The minimum sphere diameter was obtained at an ethanol
concentration of 90% according to scanning electron microscopy (SEM) and the trend of
dynamic light scattering (DLS) measurements, at a zein concentration of 0.67% (w/v),
and at a homogenizer speed of 10,000 rpm according to DLS and 15,000 rpm according
to SEM measurements. DLS measurements of the same samples were slightly larger than
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SEM measurements as is the case with the data presented in this thesis. Using the Searle
setup of the rheometer, the effect of the shear rate was assessed, demonstrating a
minimum sphere diameter of 200 nm at a shear rate of 3000 s-1 (Zhong & Jin, 2009b).
This method of sphere formation offers a potential alternative to traditional coacervation
with different means of affecting sphere size.

Another form of coacervation used to form zein micro-nanospheres involves the removal
of ethanol, typically by evaporation, bringing about a similar decrease in ethanol
concentration and subsequently sphere formation (Hurtado-Lopez & Murdan, 2005).
Hurtado-Lopez and Murdan performed a series of studies investigating the potential of
zein as a drug and vaccine carrier. They first extensively characterized the effects of the
ratio of zein to albumin, the ratio of stabilizers, and the concentration of sodium
hydroxide as these factors had the strongest impact on sphere size and degree of sphere
formation (Hurtado-Lopez & Murdan, 2005). Evidence of the potential of sphere
property modulation, release by slow erosion, and the maintained integrity of the loaded
albumin (Hurtado-Lopez & Murdan, 2005) led to subsequent studies investigating the
degradation, adjuvanticity and immunogenicity of these spheres. Degradation studies in
the absence of enzymes explained the slow release of ovalbumin previously seen in PBS
as zein was very resistant to degradation; however in the presence of pepsin and
pancreatin degradation was very much accelerated. Blank spheres and ovalbumin loaded
spheres were administered intramuscularly and blank spheres were also administered
orally to two sets of mice. Sera antibodies in mice dosed with blank spheres indicated
that zein elicited the productions of anti-zein antibodies that cross-reacted with the
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ovalbumin antigen preventing the assessment of zein’s ability to act as an adjuvant. Oral
administration led to an increase in intestinal IgA levels following booster doses,
showing that mucosal tolerance had not been achieved (Hurtado-Lopez & Murdan,
2006a). The results of the degradation study led Hurtado-Lopez and Murdan to conclude
that zein microspheres were better suited for intra-muscular administration than
administration via the oral route, and their research into the immunogenicity of zein led
them to question the applicability of these spheres via either route (Hurtado-Lopez &
Murdan, 2006a, 2006b). However another study has shown in vivo biocompatibility of
implanted zein scaffolds (H.-J. Wang et al., 2007), and as will be demonstrated below,
clinical results show that concerns about the biocompatibility and immunogenicity of
zein appear to have been unfounded as adverse effects were not seen in dogs and humans
(DiBiase & Morrel, 1997; S.-J. Gong et al., 2010).

The solvent extraction/evaporation or emulsion method is also used to form zein
microspheres. This method differs from the solvent removal coacervation technique in
that the formation of microdroplets is not entirely dependent on the removal of the
solvent but rather depends on an emulsification step in a nonsolvent. The formation of
droplets by a method such as mixing is followed by solvent evaporation (Freitas, Merkle,
& Gander, 2005). Zein microspheres encapsulating abamectin, an avermectin, were
formed by this method using acetic acid, which was later extracted, as the solvent of the
dispersed phase and lecithin in mineral oil as the continuous phase. These spheres
effectively protected the encapsulated chemical from photodegradation (Demchak &
Dybas, 1997). Mathiowitz and coworkers received a patent using this technique to
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fabricate protein microspheres and coatings. Specifically, they dissolved zein in the first
solvent, 90% ethanol, and added the compound to be incorporated. They then dispersed
this solution in the immiscible continuous phase, corn oil, with agitation, and finally
removed the solvent by evaporation. This method was used to encapsulate solid zinc
insulin, soluble insulin or rhodamine B in zein microspheres. This technique was also
applicable to modified zein, namely fatty anhydride modified and deaminated zein as
described previously (Mathiowitz, Bernstein, Morrel, & Schwaller, 1993). Blood glucose
levels in diabetic rats following subcutaneous injection of zein microspheres
encapsulating insulin compared to injection of unencapsulated insulin indicated that the
microsphere provided a longer period of bioactivity. Release of insulin from deaminated
and fatty anhydride modified zein spheres also produced a reduction in blood glucose
levels for an extended period of time (Mathiowitz, Bernstein, Morrel, & Schwaller,
1993). This process is similar to coacervation in that it does not involve harsh chemicals
or high temperatures that might degrade bioactive compounds to be encapsulated or the
zein itself, and the spheres have the potential to consist of only natural compounds and
the drug (Mathiowitz, Bernstein, Morrel, & Schwaller, 1993).

Production of zein microparticles by the supercritical anti-solvent process and spraydrying has also been demonstrated. Using the supercritical anti-solvent process in which
zein solution was atomized into supercritical CO2, thereby removing the solvent and
precipitating the zein, microcapsule containing continuous matrices with internal voids
were formed. The encapsulated lysozyme was released over 36 days indicating that this
system could be used to enhance antimicrobial efficacy during the shelf-life of foods
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(Zhong, Jin, Davidson, & Zivanovic, 2009). Spray-drying zein with thymol yielded
wrinkled microparticles on the micron scale. When these particles encapsulated
lysozyme, release was highly dependent on pH and nanoscalar matrix structure. The
formulation with a continuous matrix structure showed sustained release of lysozyme at
over 49 days at pH 6 (Zhong & Jin, 2009a).

The combination of zein with other materials, usually other natural polymers, provides a
useful method of altering the spheres’ properties. Soy potein isolate (SPI)/zein spheres,
formed by an emulsification/internal gelation technique, showed sustained release
profiles of the encapsulated riboflavin in simulated gastric fluid and simulated intestinal
fluid that were dependent on the zein:SPI ratio (L. Chen & Subirade, 2009). When fed
into an artificial digestive system consisting of gastric, duodenal, jejunal and ileal
compartments, SPI/zein microspheres achieved near-zero order absorption profiles in the
jejunum and ileum. Administering the microspheres with yogurt delayed release, likely
allowing the riboflavin to reach the intestine with preserved activity (L. Chen, Hebrard,
Beyssac, Denis, & Subirade, 2010). In another study Fourier transform infrared
spectroscopy (FT-IR) and thermal analysis provided proof that chitosan could be
incorporated into zein-based microspheres by adding aqueous chitosan solution to zein
solution (Muller et al., 2011). Zein/pectin microspheres were formed by adding pectin
solution to solutions containing zein, piroxicam, bivalent metal salts, and alcohol. The
properties of the resultant spheres (loading, swelling, and yield) depended on the polymer
ratio, bivalent ion, and the molecular mass of the pectin (Mukhidinov et al., 2011).
Amoxicillin or indomethacin loaded PLGA/zein microspheres that released the drug at
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sufficient levels for antimicrobial activity over six days were prepared by spray-drying.
Again, varying the ratio of the polymers resulted in alteration in the antibiotic release as
did the hydrophilic/hydrophobic nature of the encapsulated drug (Sousa, LuzardoAlvarez, Perez-Estevez, Seoane-Prado, & Blanco-Mendez, 2010). The studies discussed
above give examples of the ways in which zein can be combined with other compounds
to yield spheres with altered properties, specifically changes in release kinetics. In the
future, combining zein with another polymer may provide better release profiles and
transfection efficiencies for zein/DNA nanospheres.

Zein microspheres have not been limited to in vitro studies, but have successfully been
applied in vivo and in clinical applications. In the early 1990’s a zein microsphere-based
system for protein delivery called OraLease® was produced by Alkermes (DiBiase &
Morrel, 1997). Several peptides and proteins were successfully encapsulated including
calcitonin, erythropoietin, desmopressin (dDAVP), vasopressin, and insulin. The
efficacy of the system was based on the properties of zein that allowed the system to
protect the payload from the pH and enzymes of the stomach and small intestine, increase
the residence time of drugs in the GI tract, and improve the transport of drugs from the
lumen of the GI tract into the body. The dDAVP formulation was evaluated in a Phase I
clinical trial. Results showed that the drug delivery system was well tolerated, safe and
physiologically effective with a dose-dependent response (DiBiase & Morrel, 1997).
More recently, tablets composed of compressed zein microspheres encapsulating
ivermectin were evaluated in dogs receiving treatment for demodicidosis. These tablets
had similar pharmacokinetic parameters to a commercially available treatment
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formulation, with an improved bioavailability factor. The administration of a full dose or
higher of ivermectin in zein microsphere tablets resulted in a 100% curative ratio, the half
dose had a curative ratio of 93%, and the commercially available formulation had a
curative ratio of 92%. Dogs given a triple dosage of ivermectin in zein tablets showed no
adverse side effects indicating a high degree of safety and low toxicity (S.-J. Gong et al.,
2010). These studies demonstrate that the efficacy of zein nano- and microspheres,
specifically for oral administration, predicted by in vitro studies does in fact translate to
in vivo administration. Based on the clinical trial of a zein microsphere delivery system
for dDAVP it appears that zein/DNA particles possess much promise of efficacy in vivo
and even in humans.

1.4 Objectives of thesis
The objectives of this thesis are to fabricate and characterize pDNA loaded zein
nanospheres as well as to preliminarily evaluate their potential for application in oral
gene delivery. Nano- and microsphere fabrication was achieved by the coacervation
technique. Characterization entailed the measurement of sphere size and zeta potential in
PBS and water, the observation of sphere stability at various salt concentrations, the
quantification of encapsulation efficiency and loading of DNA, and the quantification of
cytotoxicity. The assessment of the nanospheres’ suitability for oral DNA delivery
involved release studies performed in pepsin and pancreatin containing solutions.
Chapter 2 describes the purpose, materials and methods, results, and conclusions of this
project, while Chapter 3 describes additional studies and possible future directions for
this project. These studies revealed that, as had been hypothesized, zein spheres
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encapsulating DNA can be formed and have the potential to be used in multiple gene
delivery applications.
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Chapter 2
Zein nanospheres for DNA delivery
Abstract
Particulates incorporating DNA are promising vehicles for nonviral gene delivery as they
have the ability to protect DNA and provide for sustained release and transfection. Zein is
a natural, hydrophobic protein from corn that is biocompatible and capable of forming
drug encapsulating nanospheres that release their payload in a controlled, enzyme
mediated manner. Zein nanospheres encapsulating DNA were fabricated using a
coacervation technique yielding particles that ranged from 157.8 ± 3.9 nm to 396.8 ± 16.1
nm and from -21.8 ± 4.2 mV to -46.6 ± 1.6 mV for hydrodynamic diameter and zeta
potential measured in water, respectively. Spheres of 20:1 and 40:1 zein to DNA ratios
flocculated in PBS while spheres formed with a higher zein to DNA ratios demonstrated
limited stability in PBS. DNA encapsulation efficiency was as high as 65.3 ± 1.9% with
a maximum loading of 6.1 ± 0.2 mg DNA/g zein. Encapsulated DNA maintained a
primarily supercoiled conformation as did DNA released from the spheres. The
cumulative release of DNA from these nanospheres in PBS was 17.8 ± 0.2% over seven
days with near zero order release for the last six days of the study.

These particles

released approximately 20% of their payload in the first 30 minutes of incubation in
pepsin containing media and released over 70% of the encapsulated DNA within two
hours. In simulated intestinal fluid, release was practically instantaneous. Release
studies indicate that degradation of these spheres is primarily enzymatic. Zein/DNA
nanospheres demonstrated similar biocompatibility at high and low concentrations in two
cell lines. Spheres showed cellular association and there was evidence of internalization
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and transfection. These results indicate that nanospheres fabricated as described here are
promising particles for gene delivery in gene therapy, DNA vaccination and tissue
engineering applications.

2.1 Introduction
Gene delivery, the introduction of exogenous DNA into cells with subsequent expression,
is applicable to the fields of gene therapy (Niidome & Huang, 2002), DNA vaccination
(Donnelly, Ulmer, Shiver, & Liu, 1997), functional genomics and diagnostics (Pannier et
al., 2007), and tissue engineering (Shea, Smiley, Bonadio, & Mooney, 1999). Because of
the technical and safety issues associated with viral gene delivery, the use of plasmid
DNA (pDNA) , which has lower immunogenicity, more flexibility in transgene capacity,
and has the potential for industrial production, is an appealing alternative for gene
transfer (Mintzer & Simanek, 2009). Delivery of pDNA can result in the expression of a
therapeutic gene or induction of protective immunity (Donnelly, Ulmer, Shiver, & Liu,
1997; S. Li & Huang, 2000). Although the injection of naked DNA can lead to transgene
expression, the level and localization of expression are limited by rapid degradation by
nucleases in the serum and clearance by the mononuclear phagocyte system (Niidome &
Huang, 2002). Encapsulation of DNA has the potential to improve in vivo response and
transfection by shielding the CpG methylation patterns of plasmid DNA from the
immune system, shielding the plasmid from degradation by pH and enzymes, increasing
residence time, and providing a controlled release (Agarwal & Mallapragada, 2008).
Nano- and microspheres incorporating DNA, which administer DNA in a controlled,
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sustained, and localized/targeted manner through the use of polymer systems that entrap
DNA and release through hydrolytic or enzymatic mechanisms, have been applied to
gene therapy, DNA vaccination, and tissue engineering (Agarwal & Mallapragada, 2008;
Panyam & Labhasetwar, 2003). When designing such a DNA delivery system an
important consideration that must be made is which route of administration will be used.

Among the various routes of administration, the oral route is perhaps the most appealing
due to its associated high patient compliance and convenience. The oral route has the
additional advantages of presenting a large surface area of intestinal epithelium for
transfection and allowing treatment of regional disorders by providing access to the
luminal side of the intestine (Bhavsar & Amiji, 2007). Oral gene delivery has the
potential to treat diseases associated with the gastro-intestinal tract (GI-tract) (Page &
Cudmore, 2001) as well as systemic diseases (Rothman, Tseng, & Goldfine, 2005), and
can provide for systemic and mucosal immunity (Jones, Corris, McDonald, Clegg, &
Farrar, 1997). However, oral delivery of DNA is complicated by low pH in the stomach
and DNases in the GI-tract (Loretz, Foger, Werle, & Bernkop-Schnurch, 2006), which
degrade unprotected DNA. Particulates are considered a viable tool for the protection of
DNA from the harsh environment of the stomach and intestine (H. Chen & Langer,
1998). Previous studies have focused on poly(lactide-co-glycolide) (PLGA) and chitosan
to form DNA-loaded nano- and microspheres for oral gene delivery (Agarwal &
Mallapragada, 2008; Bowman, Sarkar, Raut, & Leong, 2008; Jones, Clegg, & Farrar,
1998; Roy, Mao, Huang, & Leong, 1999). While these delivery vehicles have been
shown to elicit the production of a therapeutic or immune response inducing protein, the
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level of protein produced is often modest with high variability (Bowman, Sarkar, Raut, &
Leong, 2008; He et al., 2005). These materials have provided a valuable proof of
concept, but due to their lack of sufficient efficacy, new polymers need to be
investigated.

Natural polymers have been applied to drug and gene delivery and tissue engineering,
and have the advantages of providing innate degradability, and bioactivity (Dang &
Leong, 2006; Malafaya, Silva, & Reis, 2007), but typically suffer from low mechanical
stability, limited ability to be processed, and a relatively short release period compared to
synthetic polymers (Panyam & Labhasetwar, 2003; Yannas, 2004). Zein, the prolamin or
storage protein from corn, has properties that make it a promising candidate material for
particulate gene delivery. Zein’s hydrophobic nature makes it insoluble under
physiological conditions, providing sustained release of encapsulated compounds
(Hurtado-Lopez & Murdan, 2006b). Degradation of zein occurs very slowly by
hydrolysis but is accelerated by the action of enzymes (Hurtado-Lopez & Murdan,
2006b) and has been shown to be especially well suited for oral delivery (DiBiase &
Morrel, 1997; S.-J. Gong et al., 2010; Parris, Cooke, & Hicks, 2005). Zein has been
shown to be biocompatible and to have degradation products that can enhance cell
proliferation (Sun, Dong, Lin, Yang, & Wang, 2005). The functional groups available on
the side chains of zein’s residues provide sites where a number of modifications,
including deamination and phosphorylation, can be made (Mathiowitz, Bernstein, Morrel,
& Schwaller, 1993). Nano- and microspheres composed of zein can be fabricated using a
simple coacervation technique, which involves no harsh solvents or high temperatures.
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Zein microparticles have successfully been used to orally deliver ivermectin in a canine
model (S.-J. Gong et al., 2010) and desmopressin in a Phase I clinical trial (DiBiase &
Morrel, 1997). Due to the promise of this natural biomaterial for drug delivery, the
objective of this study was to formulate and characterize zein nanospheres encapsulating
DNA as the therapeutic compound, and to perform preliminary investigations into the
degradation of these particles, using gastric and intestinal-specific release studies, as well
as to characterize cell cytoxicity and association.

2.2 Methods
2.2.1

Plasmid preparation

All experiments used pDsRed2-N1 (Clontech, Mountain View, CA), a plasmid encoding
for the red fluorescent protein, DsRed2. The plasmid was purified from bacteria culture
using Qiagen (Valencia, CA) reagents and stored in Tris-EDTA (TE) buffer solution
(10mM Tris, 1mM EDTA, pH 7.4) at -20oC. Only plasmids with purity of 1.8 or better
measured by 260/280 ratio (Nanodrop 2000 Spectrophotometer, Thermo Scientific,
Waltham, MA) were used.

2.2.2

Sphere preparation

Zein spheres were formed by a coacervation technique. Zein (Freeman Industries LLC,
Tuckahoe, New York) was first dissolved in 70% ethanol at pH 3 (pH adjusted with 1M
hydrochloric acid) forming a 1% w/v zein solution. Subsequently, 1 mL of 100% ethanol
pH 3 was added to 1 mL of the 1% zein solution. A total of 1 mL of DsRed plasmid DNA
(1 mg/mL in TE buffer) and TE buffer were added followed by the addition of 10mL
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ddH2O (18.2 mΩ) drop by drop while vortexing. The zein to DNA ratio was determined
by the amount of DNA solution added and ranged from 20:1 to 250:1. Blank spheres
were formed without DNA (TE buffer substituted for DNA solution). The pH of the
resultant sphere suspension was increased to 10 by the addition of 1M NaOH. Spheres
were pelleted by centrifugation at 10,000 g for 1 hr at room temperature. The supernatant
was removed and spheres were resuspended in ddH2O.

2.2.3

Sphere characterization

2.2.3.1 Field-emission scanning electron microscopy
Scanning electron microscopy (SEM, S4700 Field-Emission SEM, Hitachi, Japan) was
used to image and subsequently analyze sphere size and morphology. For SEM imaging
spheres were resusupended in 2 mL of ddH2O and lyophilized. The lyophilized powder
was placed in a thin layer on carbon tape (Electron Microscopy Sciences, Hatfield, PA)
and mounted for imaging. Spheres were then sputter coated with chromium and imaged
at 10 kV and varying magnifications. Three micrographs for each ratio were analyzed
using Image J (NIH, Bethesda, MD) to determine average sphere diameter.

2.2.3.2 Dynamic light scattering
A dynamic light scattering (DLS) analyzer (Zetasizer Nano ZS90, Malvern Instruments
Ltd, UK) was used to measure the mean diameter and particle size distribution of spheres
after dilution in either 1X Dulbecco’s phosphate buffered saline (PBS, Invitrogen,
Carlsbad, CA) or ddH2O. For dilution in PBS, spheres were first resuspended in 2 mL of
water and then diluted further with 1X PBS due to the inability of spheres to be

44

completely resuspended in PBS. Intensity mean diameter was used to express average
particle size. The same instrument was used to measure the zeta potential of the spheres
by a combination of laser Doppler velocimetry and phase analysis light scattering.
Sphere suspensions above were likewise diluted in 1X PBS or ddH2O before
measurement. Size, zeta potential and the polydispersity index (PdI) were measured
directly after resuspension and 3 hours after resuspension for each sample to assess
stability.

2.2.3.3 Aggregation
To determine the cause of aggregation and flocculation of the spheres in PBS and the
inability of pelleted spheres to be resuspended in PBS, sphere size and zeta potential were
similarly measured by DLS at various salt concentrations. The spheres were resuspended
and diluted in ddH2O with NaCl concentrations of 300, 150, 50 and 10 mM or 1X PBS.
Size and zeta potential were measured before centrifugation and again after
centrifugation and resuspension. The degree of resuspension was noted for all
conditions.

2.2.3.4 Encapsulation & loading
DNA encapsulation within the spheres was quantified using a standard
phenol/chloroform extraction followed by fluorescent staining with Hoechst 33258
(Invitrogen). After sphere preparation and centrifugation, the supernatant was removed
to a separate conical test tube and pelleted spheres were resuspended in 5 mL ddH2O. An
equal volume of phenol/chloroform/isoamyl alcohol 25:24:1 (Fisher BioReagents, Fair
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Lawn, NJ) was added to both the sphere and the supernatant solutions and these solutions
were vortexed. The solutions were then centrifuged at 10,000 g for 15 minutes at 4°C
and then the top, aqueous layer was removed to separate tubes to which 0.5 volume of
chloroform (Fisher Chemical, Fair Lawn, NJ) was added followed by vortexing.
Solutions were again centrifuged at 10,000 g for 15 minutes at 4°C and the top, aqueous
layer was then removed to separate tubes which were centrifuged at 10,000 g for 15
minutes at 4°C to separate any residual chloroform from the aqueous layer. Any organic
layer present was removed from the bottom of the tubes. The volumes of the aqueous
DNA solutions were measured. A Hoechst standard curve was produced by graphing raw
fluorescence as measured by a fluorometer (Modulus Luminometer/Fluorometer 9200001, Turner Biosystems, Sunnyvale, CA) versus DNA concentration for various dilutions
of the stock DNA solution. Samples extracted from spheres and supernatants were diluted
appropriately in 1X TNE buffer (10mM Tris; 0.2M NaCl; 1mM EDTA; pH 7.4) and
measured after 5 minutes incubation at room temperature with one volume Hoechst dye
solution (200 ng/mL). The standard curve was then used to quantify the amount of DNA
in the sphere and supernatant extraction solutions. The mass balance for DNA was
closed between 80% and 101% as measured by recovery:

Eq. 1
Percent encapsulation was calculated as

Eq. 2
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For each sphere preparation ratio of zein to DNA, the mass of DNA in spheres per mass
of spheres was computed, using measurements of DNA encapsulation described above
and mass of lyophilized spheres for each ratio, as

Eq. 3

2.2.3.5 DNA integrity
The integrity of the encapsulated plasmid was analyzed by agarose (1%) gel
electrophoresis. Sphere extraction solutions and release samples (as described below)
were analyzed for plasmid integrity. DNA was detected using ethidium bromide (Fisher
BioReagents). A Kodak gel documentation system (EDAS 290, Kodak, Rochester, NY)
was used to capture digital images of the gels.

2.2.4

Release studies

For release studies, pelleted spheres were resuspended in 2 mL ddH2O. Separate samples
for each time point were prepared by diluting 150 μL of sphere suspension in 3 mL of
release media. These samples were incubated in a humidified 37°C chamber for varying
times. At predetermined time points, an entire sample was removed from the incubator
and spheres were separated from the supernatant by centrifugation. The spheres and the
supernatant were extracted with phenol/chloroform and DNA was quantified by Hoechst
assay, both as described above.
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DNA release from spheres into 1X PBS was measured over 7 days. Samples for loaded
and blank spheres were centrifuged at 0, 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, and 168
hours. At each time point, samples were centrifuged at 10,000 g for 30 minutes at room
temperature to separate spheres from the supernatant and analyzed as described above.
Release was calculated:

Eq. 4
For enzyme release studies, either pepsin or pancreatin were used. To simulate gastric
release, pepsin (MP Biomedicals, Solon, OH) in 0.01 M KH2PO4-citrate buffer, pH 3.5,
as previously described (Parris, Cooke, & Hicks, 2005) with the omission of Tween 20,
was prepared and added to zein sphere aliquots as described above(final 10:1 w zein/w
pepsin). Entire samples were removed from the incubator at 0, 20, 40, 60, 80, 100, 120,
180 and 240 minutes. Samples were then centrifuged at 10,000 g for 15 minutes at room
temperature and analyzed. Because DNA was degraded in the release media, release was
calculated according to the mass of DNA remaining in the spheres with the mass of DNA
in a 150 μL sphere suspension aliquot as the denominator:

Eq.5
Pancreatin (MP Biomedicals)-containing release media was made according to the USP
XXIX protocol for simulated intestinal fluid (SIF). Briefly, 3.4 g of monobasic
potassium phosphate (MP Biomedicals) was dissolved in 125 mL ddH2O water, to which
38.5 mL of 0.2 N NaOH, 250 mL water, and 5 g of pancreatin were added. The pH of
the solution was raised to 6.8 with 0.2 N NaOH and the volume was increased to 500 mL.
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A volume of 3 mL of SIF was added to the sphere suspension aliquots as described
above. Aliquots were removed at 0, 20, 40, 60, 90, 120, 150, 180, 240, 300, and 360
minutes. Suspensions were centrifuged for 15 minutes at 10,000 g and room temperature
and analyzed. Release was calculated in the same manner as PBS release:

Eq.6
Because enzymatic degradation by pepsin or pancreatin was not stopped prior to
centrifugation of the spheres, time of centrifugation was included in the time on the
release graph.

2.2.5

Cellular response

2.2.5.1 Cell culture
Human embryonic epithelial kidney cells, HEK 293T (ATCC, Manassas, VA), were
cultured in T-75 flasks in Dulbecco’s modified Eagle’s medium (DMEM,
Gibco/Invitrogen, Carlsbad, CA) containing 4.5 g/L glucose and supplemented with 10%
fetal bovine serum (FBS, Gibco), 2 mM L-glutamine (Gibco), and 1%
penicillin/streptomycin (Gibco). For seeding, cells were counted using a hemocytometer
and trypan blue staining for viable cells after being dissociated with 1mM EDTA. Human
colon carcinoma cells, Caco-2, were obtained from ATCC and were cultured in T-75
flasks in Eagle’s minimum essential medium (EMEM, ATCC) supplemented with 20%
FBS (Gibco) and 1% penicillin/streptomycin (Gibco). For seeding, cells were dissociated
with 0.05% trysin/EDTA (Gibco). For both cell lines, cells were seeded into 48 well
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plates or 8 well Nunc Lab-Tek chambered coverglass slides (Thermo Scientific) at a
density of 30,000-33,000 cells per well for HEK 293-T cells and 25,000 cells per well for
Caco-2 cells.

2.2.5.2 Cytotoxicity
Cytoxicity was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay kit (Invitrogen). Cells were seeded in 48 well
plates as described above and after 18 hours of culture, zein nanospheres containing DNA
were added to the culture media. Nanospheres were formed at a zein to DNA ratio of
80:1 and resuspended in 1 mL ddH2O prior to delivery to cells. Spheres containing 0.05,
0.1, 0.25, 0.5, 1.0 or 2.0 μg of DNA were then diluted in OptiMem (GIbco) to a final
volume of 75 μL and were added to triplicate wells. Cells were imaged to observe cell
morphology (Leica DMI 3000B, Bannockburn, IL) and the MTT assay was conducted 24
hours after the addition of zein nanospheres. The assay kit was used according to the
manufacture’s protocol scaled up appropriately for 48 well plates. Assays were
performed in triplicate on duplicate days.

2.2.5.3 Confocal microscopy
To verify that confocal microscopy could be used to image zein/DNA nanospheres
without labeling, the autofluorescence of zein was investigated. The autofluorescence of
various zein concentrations in 70% ethanol was measured in a fluorometer with
ultraviolet and blue modules. Confocal microscopy was used to assess cellular
morphology in response to the zein nanospheres, as well as to analyze cellular association
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of the spheres. Caco-2 and HEK 293T cells cultured with 80:1 or 250:1 nanospheres were
imaged using a confocal microscope (Olympus IX 81, Olympus, Center Valley, PA).
Cells were seeded as described above into 8 well coverslides. Zein spheres, which
exhibit autofluorescence were visualized with an excitation wavelength of (405 nm) and
an emission wavelength of (590 nm) and these images were overlayed with
corresponding phase images.

2.2.6

Statistics

All experiments were performed between three and six times. Comparative analyses were
completed using a student’s t-test or one-way ANOVA followed by Tukey’s multiple
comparison test for multiple data points, both at a 95% confidence level using Prism
software (GraphPad Prism 5, LaJolla, CA). Mean values with standard error of the mean
(SEM) are reported for all data.

2.3 Results & Discussion
2.3.1

Sphere formation

Coacervation, the separation of solutions into colloidal systems with two liquid phases
(Gander, Blanco-Prieto, Thomasin, Wandrey, & Hunkeler, 2006), was used to form
spheres. This separation involves the formation of one phase rich in polymer (the
coacervate) and another lacking polymer, which is brought about by the partial
desolvation of a previously dissolved polymer (Arshady, 1990; Gander, Blanco-Prieto,
Thomasin, Wandrey, & Hunkeler, 2006; Madan, 1978). Decreasing the ethanol
concentration of dissolved zein solutions by the addition of aqueous solutions results in
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the necessary desolvation and the formation of a zein-rich nanosphere phase (HurtadoLopez & Murdan, 2005). This method has been previously used to encapsulate a variety
of drugs (Fu, Wang, Zhou, & Wang, 2009a; Liu, Sun, Wang, Zhang, & Wang, 2005;
Suzuki et al., 1989; H.-J. Wang, Lin, Liu, Sheng, & Wang, 2005), however, to the best of
our knowledge, no studies have reported on the encapsulation of DNA in zein. In this
study, DNA was included with the aqueous solution, which resulted in the encapsulation
of DNA within the zein nanosphere phase formed through coacervation, thus resulting in
spheres that incorporated DNA. Encapsulation of hydrophilic DNA within the
hydrophobic zein spheres was enhanced by lowering the pH of the initial ethanolic zein
solution, which resulted in a net positive charge on the protein due to its higher isoelectric
point (Cabra et al., 2005). This change in charge promoted the electrostatic interaction of
the zein and the negatively charged plasmid DNA. Zein nanospheres formed by
coacervation and encapsulating DNA formed a suspension free of visible aggregates
during formation while blank spheres aggregated slightly (data not shown). These
observations indicate that the DNA may act as a stabilizer for zein nano- and microsphere
dispersions. Zein nanospheres centrifuged at a pH less than 9 could not be resuspended
(data not shown). By raising the pH to above 9, in this study the pH was raised to 10, the
surface charge of the spheres was lowered to ~-70 mV (a value sufficiently far from zero)
resulting in sufficient repulsive forces between spheres to prevent irreversibly
aggregation of the pelleted spheres. This sphere formation procedure allowed for the
simple and repeatable production of DNA-loaded nanospheres which were then
characterized.
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2.3.2 Characterization
2.3.2.1 SEM
The morphology and size were characterized for zein/DNA nanospheres using SEM
images. SEM images confirmed the spherical nature of the nanospheres with smooth
surfaces (Figure 2-1) at all ratios of zein to DNA. Average sizes measured from SEM
images were 73.0 ± 0.8 nm (Figure 2-1A), 95.4 ± 1.0 nm (Figure 2-1B), 133.2 ± 1.5 nm
(Figure 2-1C), 196.1 ± 2.6 nm (Figure 2-1D), and 270 ± 4.5 (Figure 2-1E) for 20:1, 40:1,
80:1, 160:1 and 250:1 spheres respectively (Figure 2-1F). The spheres prepared in this
study were relatively small compared to zein nanospheres encapsulating various
compounds prepared by similar methods (Fu, Wang, Zhou, & Wang, 2009a; Liu, Sun,
Wang, Zhang, & Wang, 2005; Parris, Cooke, & Hicks, 2005; H.-J. Wang, Lin, Liu,
Sheng, & Wang, 2005). Sphere size increased linearly as the zein to DNA ratio increased.
This increase could be due to a lower mass of DNA associated with the surface which
may result in an increase in interfacial tension between the hydrophobic sphere surface
and the aqueous medium, leading to a greater radius of curvature (Hurtado-Lopez &
Murdan, 2005). The increase in sphere size with an increase of zein to incorporated
compound has been reported elsewhere (Hurtado-Lopez & Murdan, 2005). This data
suggests that the amount of DNA present affects the nucleation and growth of zein/DNA
nanospheres and that size can be controlled by adjusting the zein to DNA ratio.
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Figure 2-1: SEM of zein-DNA nanospheres formed at 20:1 (A, 90k magnification),
40:1 (B, 90k), 80:1 (C, 60k), 160:1(D, 60k), 250:1 (E, 30k) zein:DNA ratios; average
diameter for each ratio measured from SEM images (F), reported as mean ± SEM.

2.3.2.2 DLS
Size and zeta potential were measured to further characterize and assess the stability of
zein/DNA nanospheres. Immediately after resuspension, the hydrodynamic diameters of
zein/DNA nanospheres measured in water increased with increasing zein:DNA ratio for
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40:1, 80:1, and 160:1 zein: DNA ratios (157.8 ± 3.9 nm, 266.5 ± 28.2 nm, and 385.6 ±
25.0 nm, respectively), similar to the trend observed in SEM images, however there were
not significant differences in size between 20:1 (178.9 ± 10.9 nm) and 40:1 and between
160:1 and 250:1 (396.8 ± 16.1 nm) for spheres measures by DLS (Figure 2-2A). The
average measured diameter from DLS analysis was found to be greater than the
corresponding diameter measured by SEM for all ratios (Zhong & Jin, 2009b), which
may be attributed to the presence of residual solvent in the spheres that had not been
dried, and/or swelling, which has been reported for zein fibers in an aqueous medium
(Jiang & Yang, 2011) due to zein’s hygroscopic character (Gennadios & Weller, 1994).
Zein nano- and microspheres were, for the most part, stable in water over three hours,
although 20:1 and 40:1 zein:DNA nanospheres exhibited a significant increase in
diameter over the three hours of incubation in water, indicating the possibility of limited
aggregation at these ratios. For all zein:DNA ratios PdIs varied between 0.2 and 0.1
demonstrating uniformity of the spheres (Figure 2-2C).

Size and PdI measurements, over 10 μm and 0.5, respectively, for 20:1 and 40:1
zein:DNA spheres in PBS align with the observation of flocculation at these ratios
(Figure 2-2B, 2-2D). For 80:1 and higher zein: DNA ratios, spheres did not flocculate
and measured sizes were much lower than those of 20:1 and 40:1 particles in PBS, but
were still higher than those measured in water. Larger sizes, between 740 and 1120 nm,
measured in PBS were attributed to salt induced aggregation (Everett, 1988), which was
subsequently verified. Spheres formulated at the higher zein:DNA ratios were found to
be relatively stable over three hours in water and PBS. The zeta potentials of the spheres
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formed at the various zein to DNA ratios were relatively uniform in both water and PBS,
with values distributed between -20 and -50 mV (Figure 2-2E,2-2F). Negative values
were expected as zein has an isoelectric point of 6.8 (Cabra et al., 2005) and DNA is also
negatively charged at physiological pH.

Overall, the characteristics of the zein/DNA nanospheres formulated in this study suggest
that the spheres are well suited for oral administration, particularly for DNA vaccination,
as particles less than 10 μm in diameter are taken up transparacellularly by Peyer’s
patches in the intestine (O'Hagan, 1996), a target for DNA encoding antigens because of
their proximity to gut-associated lymphoid tissue (Clark, Jepson, & Hirst, 2001).
Stabilization of the 20:1 and 40:1 particles could lend them to oral administration for
gene therapy where widespread transfection is desired since particles less than 200 nm in
diameter are taken up by endocytosis by intestinal enterocytes (O'Hagan, 1996). While
the negative surface charge measured for the zein/DNA spheres may prevent favorable
interactions with the negatively charged cell membrane, a negative surface charge may
impart mucoadhesive properties to the particles, which could increase intestinal residence
time (Hombach & Bernkop-Schnurch, 2010), further enhancing the ability of these
particles to be used for oral administration of DNA therapeutics. Although the efficacy
of the zein/DNA nanospheres formulated as described in this study could possibly benefit
from stabilization under physiological conditions and alteration of the surface charge, the
spheres have appropriate size and uniformity for oral delivery of genes.
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Figure 2-2: Size, PdI, and zeta potential for zein/DNA nanospheres formed at
various zein to DNA ratios measured directly after resuspension (0 hours, )
and three hours after resuspension (3 hours, ) in water (A, C, E) or PBS (B,
D, F). Data points labeled with the same letter are not significantly different,
while those labeled with asterisks vary significantly between the zero hour
and 3 hour measurements. All data points are reported as mean ± SEM, with
n=6
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2.3.2.3 Aggregation
Since aggregation in PBS of the zein/DNA particles was observed at all zein:DNA ratios
and flocculation took place at 20:1 and 40:1 zein:DNA ratios, the cause of this instability
was investigated. It is known that the salt concentration of the suspension solution can
affect the stability of a colloidal system (Everett, 1988), so this variable was investigated.
When resuspended in water (pH 7-8) with varying concentrations of sodium chloride, the
degree of sphere resuspension observed varied. The 80:1 zein to DNA ratio was selected
for the investigation of the effect of salt concentration because this ratio did not
flocculate, which can cause the size reading to exceed the limit of the DLS instrument.
As with PBS, most of the spheres remained pelleted in 300 mM and 150 mM NaCl, while
most but not all of the pellet was resuspended in 50 mM NaCl, and spheres were
completely resuspended in 10 mM NaCl. The size of the spheres that were able to
resuspend in PBS, 300 mM, 150 mM, and 50 mM NaCl was significantly larger than
their initial size indicating aggregation (Figure 2-3A). Also the PdI, which can
sometimes serve as an indicator of aggregation, was high for spheres resuspended in PBS
and 300 mM NaCl (Figure 2-3B). Although the measured zeta potentials were not
different for the various salt concentrations (Figure 2-3C), it appears that electrostatic
shielding due to salt concentration resulted in the destabilization and increase in the
measured size of 80:1-250:1 particles (Figure 2B) and flocculation of 20:1 and 40:1
particles (Y. Wu, Guo, Yang, Wang, & Fu, 2006). Salt concentration dependent
flocculation of zein particles was previously noted (Patel, Bouwens, & Velikov, 2010).
Based on these results, it was concluded that the salt concentration of PBS caused the
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observed aggregation or flocculation of the spheres formulated at various zein:DNA
ratios.
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Figure 2-3: Size, PdI, and zeta potential for nanospheres resuspended at various salt
concentrations (A, B, C respectively). One hour data points labeled with the same
letter do not vary significantly while asterisks in the legend denote a significant
difference between zero and one hour measurements. All data points are reported as
mean ± SEM, with n=3.

2.3.2.4 Encapsulation & loading
To determine the efficiency of DNA encapsulation for the method of sphere production
used in this study, percent encapsulation and loading were measured. Similar to sphere
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size, encapsulation and loading of DNA in zein nanospheres was dependent on the ratio
of zein to DNA (Figure 2-4). Percent of DNA encapsulation increased with the ratio of
zein:DNA up to 160:1 where it reached its maximum of 65.3% ± 1.9%. Loading was
highest with 6.1 ± 0.2 mg DNA/g zein for spheres with a zein:DNA ratio of 40:1. The
encapsulation of hydrophilic drugs in zein is more difficult to achieve than the
encapsulation of hydrophobic drugs presumably due to hydrophilic/hydrophobic
interactions. The DNA loading reported here is typical for the encapsulation of relatively
hydrophilic drugs in zein nano- and microspheres (Fu, Wang, Zhou, & Wang, 2009a; H.J. Wang, Lin, Liu, Sheng, & Wang, 2005) while higher loading (up to 190 mg drug/g
zein) has been attained by conjugating the hydrophilic drug to zein prior to particle
formation (Suzuki et al., 1989). The loading achieved in this study is also comparable to
that achieved with most PLGA nano- and microspheres (Astete & Sabliov, 2006), but is
much lower than DNA loading into chitosan/DNA nanoparticles (Mao et al., 2001).
Because nanospheres formed at a zein to DNA ratio of 80:1 did not flocculate in PBS and
had relatively high encapsulation efficiency and loading, this ratio was chosen for further
characterization and cell studies.
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Figure 2-4: Percent encapsulation ( )and loading ( )of
nanospheres prepared at various zein to DNA ratios. Data
points labeled with the same letter are not significantly
different. Data is reported as mean ± SEM with n=6.

2.3.2.5 DNA integrity
DNA integrity is necessary for efficient gene delivery, specifically maintenance of the
supercoiled conformation; thus integrity measurements were made to ensure that
encapsulation of the DNA within the zein spheres did not damage the plasmid DNA
structure. Agarose gel electrophoresis revealed that DNA was not damaged by
encapsulation under the conditions used in this study (Figure 2-5A). DNA integrity was
also maintained in spheres during seven days of incubation in PBS for the release studies,
as indicated by a supercoiled to nicked ratio similar to that of stock DNA (Figure 2-5B).
Although the nicked band appears to be larger in release samples than in the stock DNA,
there does not appear to be an increase in the ratio of nicked to supercoiled DNA over the
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seven day span of the release study (Figure 2-5C). While the stability of the DNA in and
released from zein particles is critical for oral delivery applications, it also suggests that
these zein/DNA nanospheres could be used for the fabrication of scaffolds with sustained
gene delivery in tissue engineering (Shea, Smiley, Bonadio, & Mooney, 1999), in that
this stability is superior to that of DNA encapsulated in PLGA microspheres, which
produce degradation products that lower the local pH and can degrade DNA (Jang &
Shea, 2003).
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A

B

C

Figure 2-5: Agarose gel electrophoresis image of extracted samples for spheres
made at various zein to DNA ratios (A): lane 1, ladder; lane 2, stock DNA; lane
3, 20:1 spheres; lane 4, 20:1 supernatant; lane 5, 40:1 spheres; lane 6, 40:1
supernatant; lane 7, 80:1 spheres; lane 8, 80:1 supernatant; lane 9, 160:1 spheres;
lane 10, 160:1 supernatant; lane 11, 250:1 spheres; lane 12, 250:1 supernatant;
lane 13, stock DNA; lane 14 ladder. Agarose gel image of DNA extracted from
spheres (B) and supernatants (C) at various time points in the PBS release study:
lane 1, ladder; lane 2, stock DNA; lane 3, 0 hr; lane 4, 1 hr; lane 5, 3 hr; lane 6, 6
hr; lane 7, 9 hr; lane 8, 12 hr; lane 9, 24 hr; lane 10, ladder; lane 11, 48 hr; lane
12, 72 hr; lane 13, 96 hr; lane 14, 120 hr; lane 15, 144 hr; lane 16, 168 hr; lane
17, stock DNA; lane 18, ladder.

2.3.3

Release studies

DNA release from zein nanospheres was measured in a standard PBS buffer as well as
solutions designed to mimic gastric and intestinal fluids. Nanospheres formulated at the
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80:1 zein to DNA ratio released encapsulated DNA relatively rapidly for the first 12
hours of the PBS release study (Figure 2-6). This period of fast release was followed by
a near zero order release profile for the remainder of the study. After seven days in PBS
only 17.8 ± 0.2% of the encapsulated DNA was released. Sustained release of
encapsulated drug in PBS has previously been demonstrated for zein nano- and
microspheres (Hurtado-Lopez & Murdan, 2005). These results indicate that if breakdown
occurs by hydrolysis, it does so slowly, allowing for the release of DNA in a sustained
manner over at least one week and likely much longer. This sustained release also
indicates that DNA is encapsulated within the particles rather than being absorbed to the
surface.
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Figure 2-6: Release of DNA from 80:1 zein spheres incubated
in PBS at 37°C over 7 days. Data reported as mean ± SEM,
with n = 5.
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The ability of zein nano/microspheres to protect and deliver DNA to the stomach and
intestine was investigated by performing release studies in pepsin-containing medium and
simulated intestinal fluid containing pancreatin, respectively. Release in pepsin solution
began slowly but accelerated in the first 55 minutes (Figure 2-7), possibly due to the lag
in heating of the samples as pepsin has an optimum activity temperature of 50°C (Hirano
& Miura, 1979). This acceleration was followed by near zero order release that plateaued
at 115 minutes. The cumulative release after 255 minutes was 77.5 ± 0.6% of
encapsulated DNA. Because typical residence time in the stomach is approximately two
hours for post-prandial administration (Klein, Wunderlich, Stippler, & Dressman, 2005),
and the nanospheres investigated here released over 70% of their payload in this time,
modifications may be necessary to achieve efficient oral delivery via this method of
administration. However, since pre-prandial residence time is shorter, at approximately
30 minutes (Klein, Wunderlich, Stippler, & Dressman, 2005), and at this time point about
80% of the DNA remained encapsulated, these spheres have the necessary enzyme
resistance to transport the bulk of their payload through the stomach and into the
intestine.

In simulated intestinal fluid, release was nearly instantaneous (Figure 7), indicating that
release of the DNA from the spheres was mediated by enzymes found within the
intestine. Spheres formulated as described in this study would likely deliver DNA to the
lumen of the intestine. While transfection by free DNA delivered to a patent rat
duodenum has been reported (Rothman, Tseng, & Goldfine, 2005), it is unlikely that a
high level of transfection would be achieved by free DNA in the intestine due to the

65

presence of DNases and inefficient uptake of free DNA. If these spheres are intended to
be taken up intact they must first be modified, possibly by crosslinking, to reduce their
rate of degradation by the enzymes in pancreatin. The results of the release studies
reported here are supported by release and degradation studies for zein nanospheres
encapsulating essential oils. Release was monitored in pepsin containing media,
demonstrating sustained release, and the degradation of zein incubated with swine
manure solids was measured, indicating rapid degradation (Parris, Cooke, & Hicks,
2005). The release studies performed in this study demonstrate that upon oral
administration, degradation of zein/DNA nanospheres will take place by enzymemediated mechanisms rather than hydrolysis. Synthetic biodegradable polymers like
PLGA are often degraded by hydrolysis or oxidation reactions and not by enzymes (van
Dijkhuizen-Radersma, Moroni, van Apeldoorn, Zhang, & Grijpma, 2008). Zein/DNA
nanospheres are degraded to varying degrees by enzymes in the GI-tract, which would
likely result in the delivery of the majority of their payload to the intestine upon oral
administration.
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Figure 2-7: Release of DNA from spheres in pepsin ( ) or
pancreatin ( ) containing solution. Data reported as mean ±
SEM with n = 3 for pepsin mediated release and n=6 for
pancreatin mediated release.

2.3.4

Cell studies

Cell studies were conducted to determine zein/DNA particles cytotoxicity and cellular
association/internalization. For MTT assays, absorbance values at 570 nm normalized to
control cells (without particles) showed that these particles were mildly cytotoxic to
Caco-2 cells and more cytotoxic to HEK 293T cells at all concentrations (Figure 2-8).
Chitosan/DNA nanoparticles were also shown to be more cyctotoxic to HEK 293T cells
than other cell lines (Corsi, Chellat, Yahia, & Fernandes, 2003). For both cell types there
was a lack of a dose response indicating that the presence of particles affected
proliferation to an extent, but the quantity of particles did not determine the cellular
response. Although the MTT data indicates cytotoxicity in the HEK 293T cells,
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morphology appeared normal for both cell types incubated with zein/DNA nanospheres
(data not shown). It should be noted that this was a short term study and that
proliferation levels may increase at later time points, especially since zein degradation
products have been shown to enhance cellular viability (Sun, Dong, Lin, Yang, & Wang,
2005). This type of cytotoxicity has not previously been reported for zein, possibly
because cells were seeded onto zein films rather than having zein placed on top of the
cells (Dong, Sun, & Wang, 2004; Sun, Dong, Lin, Yang, & Wang, 2005; H.-J. Wang,
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Figure 2-8: Cytotoxicity of zein-DNA nanospheres quantified
by MTT assay for Caco-2 and HEK 293T. Data bars labeled
with the same letter do not vary significantly, and columns
labeled with asterisks vary significantly between HEK 293T
and Caco-2 values. Data reported as mean ± SEM with n=6.

For confocal imaging nanospheres were not labeled as zein was observed to autofluoresce
at multiple wavelengths of excitation and emission. For example, there was a linear
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relationship between zein concentration and fluorescence for excitation wavelengths of
365-395 nm and 465-485 nm, indicating that zein autofluoresces at under these
conditions (Figure 2-9).
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Figure 2-9: Autofluorescence of zein at various concentrations using ultraviolet (365-395
nm) and blue (465-485 nm) modules.

Confocal images of HEK 293T and Caco-2 cells with added particles revealed a high
degree of particle association with both cell types (Figure 2-10). Nanospheres were
found to concentrate on cells more than in the intercellular spaces of the culture slides.
Z-series images showed that many of the spheres were located in the same area and same
plane as many cells rather than on top of cells (data not shown) indicating that particles
were likely internalized. There also appeared to be limited transfection in some images
acquired using the fluorescence microscope (data not shown) suggesting that these
nanospheres have the potential to be used to deliver DNA when properly optimized.
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A
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Figure 2-10: Confocal images of HEK 293T cells with associated 80:1 spheres (A, 60X
magnification, 0.1 ug DNA/well) and 250:1 spheres (C, 60X, 0.1 ug DNA/well), and
Caco-2 cells with associated 80:1 spheres (B, 60X, 0.1 ug DNA/well) and 250:1 spheres
(D, 60X, 0.1 ug DNA/well). It should be noted that not all of the particles fluoresced in
the images as some were out of the focal plane of the microscope.

2.4

Conclusions

Zein, a natural protein, was investigated as a possible material for the formation of
spheres encapsulating DNA for oral gene delivery. Nanospheres were formed using a
simple coacervation method, without the use of harsh solvents or temperatures, resulting
in the preservation of DNA integrity. Results from this study indicate that particles
formulated as described here were of the proper size for oral administration and the
fabrication of tissue engineering scaffolds, with tunable sizes and surface charges that
may promote intestinal retention.

DNA encapsulation efficiencies were maximized to

acceptable levels at the higher zein to DNA ratios, while loading was comparable to that
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of other hydrophilic compounds encapsulated in zein and that of DNA incorporated into
PLGA nano- and microspheres. Release studies indicate enzyme-mediated DNA
release, with sustained release in the absence of enzymes. Nanospheres also showed
good biocompatibility with the Caco-2 cell line. Microscopy of cells with
nano/microspheres indicated that the particles were highly associated with cells and were
possibly internalized with limited transfection. Future work should include the
modification of these spheres to improve the resistance to degradation by intestinal
enzymes so that intact spheres can be taken up. Modifications improving cellular uptake
and transfection should also be investigated. Zein appears to be an excellent potential tool
for the delivery of DNA with the ability to be fine tuned for specific applications
including oral gene delivery, DNA vaccination, and tissue engineering.
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Chapter 3
3.1 Introduction
In Chapter 2 zein/DNA nanospheres were formed using a simple coacervation method
and were found to be of the proper size for oral administration and the fabrication of
tissue engineering scaffolds. DNA encapsulation efficiencies were maximized to about
65% at the higher zein to DNA ratios, while loading, about 6 mg DNA/g zein, was
comparable to that of other hydrophilic compounds encapsulated in zein and that of DNA
incorporated into PLGA particles (Astete & Sabliov, 2006). Release studies indicated
that release of DNA from these spheres takes place much more quickly by enzymatic
degradation than by hydrolysis. Cell association was demonstrated by microscopy as
well as possible internalization and isolated transfection, and nanospheres showed good
biocompatibility with an intestinal cell line. Although the potential of DNA-loaded zein
nanospheres was demonstrated in Chapter 2, there is much room for improvement in the
properties of these particles to optimize for applications including not only oral delivery,
as described in Chapter 2, but also intramuscular delivery and tissue engineering
applications, as described below. DNA loading should be increased so that a lower mass
of particles can be used to deliver a sufficient dose of DNA. Current levels of
encapsulation efficiency, DNA activity, and biocompatibility should be maintained or
improved upon in the process of improving loading. Also zein/DNA spheres need to
remain stabilized against aggregation under physiological conditions. The resistance of
the particles to degradation by gastric and especially intestinal enzymes will likely need
to be enhanced to achieve sufficient in vivo transfection to be therapeutic without the
administration of an excessive amount of DNA. Internalization should be better

72

characterized and possibly increased in vitro to better facilitate transfection. A strategy
for nuclear localization may also be needed to achieve significant levels of transfection.
A Caco-2 monolayer model should be used to assess the intestinal uptake and transport of
particles in vitro, and in vivo administration and efficacy should then be assessed in an
animal model. Applications in tissue engineering and intramuscular injection should also
be explored. These improvements to the zein/DNA nanospheres formulated in this thesis
and the investigation of new applications should render them more useful and increase
the likelihood of their clinical application.

3.2 Improving loading
The current mechanism of promoting DNA incorporation into zein nanospheres namely,
the use of low pH during the first steps of fabrication to facilitate electrostatic interactions
between zein and DNA, has resulted in limited success. The maximum loading achieved
was 6.1 ± 0.2 mg DNA/g zein, and could be improved upon. These results do not mean
that the current strategy should be abandoned. Instead it may be possible to achieve
significantly higher levels of loading by optimizing the pH to improve the affinity of zein
and DNA for each other. For example Figure 3-1 shows that in a preliminary experiment
using 85% ethanol at pH 3 rather than 70% and 100% ethanol, both at pH 3, as described
in Chapter 2 to form 40:1 spheres, encapsulation efficiency was significantly improved,
corresponding to an estimated loading of 11.5 mg DNA/g zein. This difference in
encapsulation likely resulted from the unreliability of reading the pH of absolute ethanol
with a standard pH meter, meaning it is possible that the combination of 70% ethanol at
pH 3 and 100% ethanol at pH 3 did not result in a final solution with a pH of 3.
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Figure 3-1: Encapsulation efficiencies of 40:1 spheres
formed from zein dissolved in 85% ethanol at pH 3 or
equal parts of 70% and 100% ethanol, both pH 3.
Reported as mean ± SEM with n=3.

It is likely that the optimal conditions will involve the maintenance of the pH of the
sphere forming solution between the isoelectric points of DNA and zein. This pH range
should result in opposing net charges on zein and DNA. Optimization of loading in this
way may also involve altering the pH of the zein solution and the water added to induce
coacervation. This parameter was not optimized as the primary goals were to form
zein/DNA spheres and to determine how to characterize them.

If the pH-induced electrostatic interaction technique cannot be optimized to levels of
DNA loading high enough for efficient gene delivery, other chemical modifications may
be necessary. It may be possible to mimic the complexation of DNA with commonly
used cationic polymers and lipids by modifying the charge of zein using other chemical
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methods. However, it may be difficult to modify zein while maintaining its solubility
properties, which make coacervation possible, as well as its biocompatibility (Futami,
Kitazoe, Murata, & Yamada, 2007). Another method of improving loading may be the
conjugation of DNA to zein prior to sphere formation. This technique has been used to
achieve higher levels of loading for other hydrophilic drugs in zein particles (Suzuki et
al., 1989). However, this method may not be feasible as the activity of DNA modified in
this way may not be maintained. The improvement of DNA loading by a method such as
those described above should increase the efficacy of zein/DNA nanospheres at achieving
significant and sustained transfection.

3.3 Stabilization under physiological conditions
All of the nanospheres described in this thesis would likely need some sort of
modification endowing them with stability under physiological conditions to be effective
gene delivery vehicles in vivo. Particularly nanospheres produced at the 20:1 and 40:1
zein to DNA ratios need stabilization under physiological conditions. Stability of
colloids can be achieved through repulsion of particles based on surface charge or
through steric stabilization (Myers, 1999). Because electrolytes reduce the electrostatic
repulsion between particles, it may be best to sterically stabilize the zein/DNA particles.
It may be possible to stabilize the sphere using an adsorbed surfactant or a surface grafted
polymer such as poly(ethylene glycol) and polyethyleneimine (Qi, Colfen, & Antonietti,
2001), the latter of which could have the added benefit of DNA complexation (Patil,
Rhodes, & Burgess, 2005). The use of surface modifications for stabilization will have to
be balanced with the effects of the modifications on encapsulation efficiency,
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biocompatibility and transfection efficiency. For example, particles may be coated with a
cationic polymer to improve internalization (Shmueli, Anderson, & Green, 2010).

3.4 Resistance to degradation
As release studies in Chapter 2 showed, zein/DNA nanospheres are susceptible to
enzymatic degradation in the stomach and particularly in the intestine. Because
successful oral delivery of DNA will likely result from the cellular uptake of a DNA
delivery system rather than free DNA (Rothman, Tseng, & Goldfine, 2005), in this case a
particulate delivery system, it is preferred for the particles to remain intact long enough to
be taken up by the cells lining the intestine. Although the effects of crosslinking on the
enzymatic degradation of zein have not been reported, it is conceivable that this type of
modification could slow the rate of zein degradation. Citric acid should be investigated
first as a crosslinking agent, as such crosslinking may also be beneficial from a
biocompatibility standpoint. In addition to decreasing the rate of zein degradation, this
treatment may also enhance biocompatibility as fibers crosslinked with citric acid have
shown better biocompatibility than uncrosslinked zein fibers (Jiang, Reddy, & Yang,
2010). Crosslinking of zein/DNA nanospheres with citric acid was attempted but not
verified. The effect of this treatment on degradation was not, but should be, assessed.
Alternatively, encapsulating zein in or blending zein with another polymer, natural or
synthetic, with resistance to degradation in the gastrointestinal tract (GI-tract) could
possibly delay release of DNA until after the particles have been internalized (L. Chen &
Subirade, 2009). Conversely, zein may be useful as a coating for other DNA delivery
systems designed to be released in the intestine.
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3.5 Characterization & improvement of internalization
Although confocal images indicate internalization of zein nanosphreres containing DNA
by Caco-2 cells, internalization should be more definitively characterized. In Figure 32A, a confocal image taken in a plane between the top and bottom of cells, spheres
appear to be internalized and located within the cytoplasm around the nucleus of the cell
encircled in the oval. Figure 3-2B shows a plane above the cells, where if spheres were
not internalized one would expect distribution as is seen in the rectangle, indicating the
presence of spheres above the nucleus. However, this is not the case in the oval where
very little fluorescence is seen in the plane above the cell with almost none above the
nucleus.

Staining of the cell membrane would provide conclusive evidence of

internalization. Internalization, once verified, could possibly be quantified by flow
cytometry.
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A

B

Figure 3-2: Confocal images taken in the plane of the Caco-2 cells (A) and
above them (B). Also shown is a merged image of all of the fluorescence
images from the planes from the bottom to the top of cells (C).

Strategies to improve internalization, if needed, could include surface cationization,
addition of target moieties targeting cell surface receptors, and reduction in sphere size.
Surface cationization could be achieved through a number of chemical modifications
including adsorption of a cationic surfactant or surface conjugation of a cationic polymer
as previously discussed. The targeting of cell surface receptors would likely entail the
immobilization of a receptor specific ligand or a nonspecific membrane transduction
sequence on the sphere surface. Ligands including lectins and the B subunit from cholera
toxin have been investigated as possible GI-tract targeting ligands (Page & Cudmore,
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2001). Sphere size may be reduced by altering sphere formation parameters such as the
zein to DNA ratio as shown in Chapter 2 or by reducing the concentration of the initial
zein solution as shown in Figure 3-3 (preliminary results). The reduction of the
concentration of the initial zein solution from 1% to 0.33% or 0.2% w/v resulted in a
significant decrease in the nanosphere size.
400
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300

b

200
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a
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2%

0

Concentration of initial zein solution (w/v)

Figure 3-3: The effect of the initial zein concentration
on sphere size for spheres formed at 80:1 and 160:1
zein to DNA ratios. Data points labeled with the same
letter are not significantly different p>0.05. Reported
as mean ± SEM with n=6.

If sphere internalization is determined to result in transport into the cytoplasm but not
nuclear internalization as is seen in Figure 3-2A, it may be necessary to include a nuclear
localization signal (NLS) or karyophilic protein to enhance transfection efficiency (Zanta,
Belguise-Valladier, & Behr, 1999). A variety of NLSs have been used to enhance
nonviral gene delivery (Cartier & Reszka, 2002).
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3.6 In vitro & in vivo models
The Caco-2 monolayer is a commonly used model for investigating the intestinal uptake
of and transport of particles. To model the single cell layer of the intestinal epithelium,
Caco-2 cells are typically seeded onto a transwell membrane and allowed to proliferate to
the point of forming a continuous monolayer (Artursson, Palm, & Luthman, 2001). For
an M-cell model, Caco-2 cells grown on a transwell membrane are co-cultured with
lymphocytes isolated from Peyer’s patches. The presence of these cells in the co-culture
system has been shown to cause the Caco-2 cells to undergo further differentiation to Mcells (Kerneis, Bogdanova, Kraehenbuhl, & Pringault, 1997). Like most in vitro models
of in vivo tissue, these are far from perfect but have been demonstrated to have merit in
predicting the behavior of at least part of the intestine. Several studies have shown
varying correlation between the apparent permeability of the Caco-2 monolayer and the
percent of absorption in humans after oral administration (Artursson, Palm, & Luthman,
2001). Because of its extensive use in predicting the intestinal absorption of
pharmaceuticals, the Caco-2 monolayer is an obvious choice for the preliminary
assessment of intestinal uptake and transfection. The M-cell model is likewise a logical
in vitro choice for predicting the efficacy of oral delivery systems for DNA vaccination,
as M-cells are common targets for oral DNA vaccination.

In vivo studies are particularly important for the validation of this gene delivery system.
Despite in vitro results, positive or negative, in vivo studies may result in quite different
transfection efficiencies than that seen in cultured cells. For example, Saeki and
coworkers found a reciprocal relationship between the anionic or cationic nature of

80

liposomes and their efficacy in vitro and in vivo (Saeki et al., 1997). The selection of an
animal model is an important factor determining the outcome of the study. For example,
rabbits have significantly more Peyer’s patch M-cells than rodents (H. Chen & Langer,
1998) making them an appealing model for oral DNA vaccination. However, the most
commonly used models for oral gene delivery are mice. It is unclear which of the
available animal models is best for predicting the intestinal absorption of particles in
humans (H. Chen & Langer, 1998). While in vivo transfection can be quantified by
measuring the expression of a reporter gene like luciferase (normalized to tissue mass)
(Rothman, Tseng, & Goldfine, 2005), the telling indicator of successful transfection is a
physiological change in a local disease, e.g. acute colitis (Bhavsar & Amiji, 2008), model
or a systemic disease, e.g. diabetes (Rothman, Tseng, & Goldfine, 2005).

3.7 Intramuscular administration & applications
The oral route of administration is not the only route of interest for gene therapy and
DNA vaccination. The direct injection of DNA delivery systems into muscle has been
investigated for DNA vaccination (O'Hagan, Singh, & Ulmer, 2004) and gene therapy
(Tripathy et al., 1996). As is the case with intramuscular injection of naked DNA,
injection of DNA-loaded nanoparticles and microparticle into the muscle primarily
results in local transfection because the particles do not readily diffuse from the tissue.
Transfection of muscle cells can elicit an immune response (O'Hagan, Singh, & Ulmer,
2004), can result in a physiological change in the injected muscle (Shyu, Manor, Magner,
Yancopoulos, & Isner, 1998), or can serve as a depot releasing the encoded protein into
circulation (Tripathy et al., 1996). Particulate DNA delivery vehicles have been shown to

81

increase the magnitude and duration of transgene expression compared to other delivery
vehicles or naked DNA administered intramuscularly. Compared to DNA complexed
with lipofectamine, intramuscular delivery of nanospheres produced expression of
plasmid DNA that was one or two orders of magnitude higher after seven days and was
more sustained (Agarwal & Mallapragada, 2008). Intramuscular administration of DNA
encapsulated in poly(2-aminoethyl propylene phosphate) resulted in enhanced
transfection relative to naked DNA (J Wang, Zhang, Mao, & Leong, 2002). Similarly
zein nanoparticles that have been stabilized under physiological conditions and that can
facilitate uptake should be good DNA delivery vehicles via this route of administration.

3.8 Tissue engineering & applications
Tissue engineering is the application of engineering and biology to the development of
functional substitutes for damaged or diseased tissues (Langer & Vacanti, 1993).
Constructs for tissue engineering can consist of three components, namely the scaffold
(the physical structure), cells (which make up the new tissue), and bioactive signals
(which direct cellular function)(Langer & Vacanti, 1993). The integration of gene
delivery and structural support into tissue engineering scaffolds has the potential to
greatly enhance tissue repair in the case of injury or disease. The physical structure of
the scaffold allows for the creation and maintenance of space for cell adhesion and
migration, serves as a depot for sustained gene delivery, and controls the cellular
environment of gene transfer (Agarwal & Mallapragada, 2008). Using this controlled
manner of transfection, direction of cell function can be achieved. DNA can be
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incorporated into tissue engineering scaffolds through encapsulation within the scaffold
material or immobilized to the scaffold surface (De Laporte & Shea, 2007).

Gong and coworkers formed zein scaffolds by particle leaching in an 85°C water bath,
resulting in scaffolds that ranged in porosity from 75.3% to 79.0% and varied in
mechanical properties with a compressive Young’s modulus of 28.2-86.6 MPa and
compressive strength of 2.5-11.8 MPa. These properties were found to be suitable for
application in non-load bearing bone tissue engineering (S. Gong, Wang, Sun, Xue, &
Wang, 2006). If this technique cannot be used with zein/DNA nanospheres, a gas
foaming, particulate leaching technique similar to that used for the fabrication of DNAloaded PLGA microsphere scaffolds is another possibility for scaffold formation (Jang &
Shea, 2003). It is possible to improve the mechanical properties of zein scaffolds,
specifically their brittleness by the addition of plasticizers such as oleic acid (H.-J. Wang
et al., 2007). Similarly, the bioactivity of the scaffold can be improved upon. For
example, zein scaffolds were coated with hydroxyapatite by submerging them in
simulated body fluid. These coated scaffolds resulted in higher alkaline phosphatase
activity in seeded human bone marrow stroma cells, indicating a greater degree of
differentiation to bone (Qu et al., 2008). Zein scaffolds (not coated in hydroxyapatite)
were later implanted ectopically in mice and in critical-sized bone defects. Scaffolds
seeded with MSCs showed markedly more bone formation in both cases than scaffolds
without MSCs and the control (Tu et al., 2009). These studies indicate the promise of
zein scaffolds in tissue engineering. The use of DNA-loaded zein nanospheres as the
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building blocks of a similar scaffold could further improve the bioactivity and thus the
performance of tissue engineering constructs.

3.9 Conclusions
In this thesis, a technology for gene delivery consisting of zein nanospheres
encapsulating DNA has been established. These particles show great promise for oral
DNA delivery, but could use modification to improve several properties pertaining to
stability, uptake and transfection in vitro and in the GI-tract in vivo. Additionally
applications in tissue engineering and intramuscular injection should be investigated as
zein/DNA particles may also prove to be an effective tool for transfection in these
applications.
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Appendix A:
Encapsulation and Size Data for Zein Microspheres Encapsulating Compounds

Material

Compound
Loaded

Preparation Methods

Size

Encapsulation
Efficiency
(% w/w)

Loading
(% w/w)

Source

22.9 μm

22.9

9.2

Chen & Subirade,
2009

20.8-25.5 μm

79.3-87.9

8.9-9.8

Chen & Subirade,
2009

Zein

riboflavin

emulsification

Soy protein
isolate/Zein

riboflavin

emulsification/ internal
gelation

Zein

abamectin

emulsification

< 70 μm

35

NR

Zein

ciprofloxacin

coacervation

0.5-2 μm

4.97-8.29

0.87-2.41

Zein

none

coacervation

1.36 μm

N/A

N/A

Hurtado-Lopez &
Murdan, 2005

Zein

ovalbumin

coacervation

210-1882.9 nm

53.9

23.9

Hurtado-Lopez &
Murdan, 2005

Zein

ivermectin

coacervation

0.3 - 1.2 µm

24.73-68.51

4.05-17.16

Zein

solid zinc insulin

solvent
evaporation/extraction

3.2 µm

NR

4.8 or 9

Mathiowitz et al.,
1993

Zein

insulin

solvent
evaporation/extraction

NR

NR

17-42

Mathiowitz et al.,
1993

Modified
Zein *

insulin

solvent
evaporation/extraction

NR

NR

17

Mathiowitz et al.,
1993

Zein

polysaccharide-K

conjugation and
coacervation

< 1 μm

4.2-34.5

NR

Matsuda et al.,
1989

Pectin/Zein

piroxicam

gelation/coacervation

NR

9.8-95.2

NR

Zein

gitoxin

coacervation

1-1.7 μm

1.77-20.98

0.31-3.17

Zein

essential oils

coacervation

~100 nm

NR

20 or 13

Parris et al., 2005

Zein

amoxicillin

spray-drying

9.4 µm

NR

NR

Sousa et al., 2010

Zein

indomethacin

spray-drying

5.6 µm

99

5.8

Sousa et al., 2010

PLGA/Zein

amoxicillin

spray-drying

28.05 or 38.3 µm

45.3 or 38.7

2.4 or 2.1

Sousa et al., 2010

PLGA/Zein

indomethacin

spray-drying

18.5 or 38.5 µm

91.8 or 85.8

5.4 or 5.1

Sousa et al., 2010

Zein

mitomycin C

conjugation and
coacervation

< 1 µm

NR

16.4 or 30.0

Suzuki et al.,
1989

Zein

daunomycin
hydrochloride

conjugation and
coacervation

NR

NR

31.3

Suzuki et al.,
1989

Zein

peplomycin sulfate

conjugation and
coacervation

NR

NR

7.6-19.0

Suzuki et al.,
1989

Zein

heparin

coacervation

40-100 nm

1.97-22.77

0.34-3.67

Wang et al., 2005

Zein

lysozyme

supercritical anti-solvent

< 50 µm

46.5

NR

Zhong et al., 2009

Zein

lysozyme

spray-drying

NR

35.4-49.1

NR

Zhong et al., 2009

Demchak &
Dybas, 1997
Fu et al., 2009

Liu et al., 2005

Mukhidinov et
al.,2011
Muthuselvi &
Dhathathreyan,
2006

